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Abstract 
Multiple sclerosis (MS) and type 1 diabetes (T1D) are autoimmune diseases where 
the immune system produces antibodies against the body’s own tissue. The immune 
response in MS is caused by B- and T-cells that attack the myelin sheaths’ auto-
antigens in the central nervous system, which results in demyelination and plaques.  
In T1D the immune response targets the β-cells in the pancreas, where insulin 
deficiency will happen due to the destruction of the β-cells. Studies show that genetic 
factors as well as vitamin D affect the progression of MS and T1D. The specific 
HLA-DRB1*1501 gene is associated with the development of MS, whereas the HLA-
DRB1, HLA-DQA1, and HLA-DQB1 are associated to T1D. Both diseases are 
associated with the HLA-DRB1 gene encoding the MHC class II molecule, which 
could indicate a shared inheritance and could explain the reason why an individual 
with the organ specific disease MS has a bigger risk of developing the organ specific 
and systemic autoimmune disease T1D, or vice versa.  
Vitamin D3 has been shown to have a preventive effect on the development of both 
diseases. Calcitriol, which is the active metabolite of vitamin D, restores the balance 
between the immune cells T-regs, Th-1, Th-2 and Th-17. The suppression of Th-1 and 
Th-17 cells reduces the number of pro-inflammatory cytokines, which results in a 
reduced autoimmune response. MS and T1D are more frequently developed in Nordic 
countries compared to countries near equator due to the low sun exposure.  
Abstrakt 
Multipel sklerose (MS) og type 1 diabetes (T1D) er autoimmune sygdomme, hvor 
immunsystemet danner antistoffer mod kroppens eget væv. Immunresponset i MS er 
forårsaget af B- og T-celler, der angriber myelin skedernes autoantigener i 
centralnervesystemet, hvilket medfører demyelinering og plaks.  
I T1D er immunresponset rettet mod bugspytkirtlens β-celler, hvor insulinmangel vil 
forekomme grundet destruktion af β-cellerne. Studier viser at genetiske faktorer samt 
D vitamin påvirker udviklingen af MS og T1D.  Det specifikke HLA-DRB1*1501 
gen er associeret til udviklingen af MS, hvor generne HLA-DRB1, HLA-DQA1 og 
HLA-DQB1 er knyttet til T1D.  Begge sygdomme udtrykker genet HLA-DRB1 der 
danner MHC klasse II molekylet, hvilket kunne tyde på en fælles nedarving samt 
dokumentere grunden til at et individ med den organspecifikke autoimmune sygdom 
MS, har større risiko for at udvikle den organspecifikke og systemisk autoimmune 
sygdom T1D, eller omvendt. 
D3 vitamin har vist at have en forebyggende effekt på udviklingen af begge 
autoimmune sygdomme. Calcitriol, som er den aktive metabolit af D vitamin, 
genopretter balancen mellem immuncellerne T-regs, Th-1, Th-2 og Th-17. 
Suppressionen af Th-1 og Th-17 celler reducerer antallet af pro-inflammatorisk 
cytokiner, hvilket resulterer i et reduceret autoimmunt respons.  
Grundet en lav sollys eksponering, udvikles MS og T1D derfor hyppigere i nordiske 
lande end i lande nær ækvator.  
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Introduction 
Multiple Sclerosis (MS) is an autoimmune disease, which is caused by a response of 
the body’s immune system towards the central nervous system (CNS). The immune 
system specifically attacks and degrades the myelin sheaths that surround the axons of 
neurons. The myelin sheaths and axons are responsible for efficient nerve impulses 
travelling to, from, and between the brain and spinal cord (National Multiple Sclerosis 
Society, 2014b; Scleroseforeningen, 2013a).  
The degraded myelin sheaths form scar tissue, also called plaques, in the CNS. This 
causes weakness of nerve impulses, which causes symptoms like cognitive, physical, 
and mental changes (Scleroseforeningen, 2013a, 2013c).   
More than 2.3 million people worldwide are affected by MS, and seven to eight out of 
ten patients are women (National Multiple Sclerosis Society, 2014a).  
Studies show that genetics and environmental factors influence the risk of developing 
the disease (Cree, 2014; Goris, Pauwels, & Dubois, 2012; Pierrot-Deseilligny & 
Souberbielle, 2013).  
This project examines the influence of genetics and vitamin D in regards to the risk of 
developing MS and Type 1-Diabetes (T1D). T1D is an autoimmune disease in which 
the immune system targets and degrades the pancreatic β-cells. The β-cells produce 
and secret insulin and the destruction of these therefore result in an insufficient insulin 
production or with further disease progression, complete insulin deficiency. This 
causes an inability of the cells to assimilate glucose. T1D primarily affects younger 
people and is the second most common chronic disease in children (Wolden-Kirk, 
Overbergh, Christesen, Brusgaard, & Mathieu, 2011). 
Furthermore we examine potential similarities in the development of both 
autoimmune diseases. In this project we will answer the question:  
 
Is it a coincidence that people whom are affected with Multiple Sclerosis develops 
another autoimmune disease such as Type 1 Diabetes, and is it likely that genetic 
factors and vitamin D insufficiency could be a reason why these autoimmune diseases 
occur?  
 
This project is written to bachelor students in 2nd year of medical biology with 
limited knowledge of immunology. The project is built up around a theory section, 
which will give the reader a basic understanding of the scientific elements such as the 
immune system, autoimmunity, MS, and T1D. The susceptibility to MS and T1D will 
also be elaborated, and vitamin D’s influence on these.    
These sections in the theory are necessary for the following analysis and discussion, 
in which the project will address the following issues: Connections between T1D and 
MS regarding the genetic disposition and the role of vitamin D. 
 
Furthermore we have a list containing definitions of biological words and terms, 
which can be found in appendix 1.  
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Theory section 
Innate immunity 
The innate immune system is the first acting defence against foreign substances and 
pathogens. To enter the body the pathogens first have to pass the physical barriers and 
the non-cellular defence, which is the first part of innate immune system. If they 
manage to get past these defences, there is a cellular defence, which is the second part 
of the innate immune system (Goldsby, Kindt, Osborne, & Kuby, 2003). This defence 
cooperate with the adaptive immune system, which will be explained in the following 
section.  
 
The physical barriers and non-cellular defences include the skin and the surface of the 
mucous membrane. Pathogens have to cross these physical barriers to enter the body. 
The skin and mucous layers are not the only defence keeping the microorganisms 
from entering the body. Saliva, tears, and mucous secretions are examples of defences 
aiding in the prevention of an infection. All these substances contain lysozyme, an 
antibacterial enzyme, which is able to cleave the peptidoglycan layer of the bacterial 
cell wall, thereby cleaving the cell into smaller pieces. This causes the pathogens to 
undergo necrosis (Goldsby et al., 2003). Some other non-cellular factors also 
contribute to the defence against invading pathogens. One factor is temperature 
sensitivity and another is pH value. The pH value of the gastric acid is approximately 
pH 3, which mean that no ingested pathogens are able to survive passing through this 
environment. This way, the body is protected from most of the pathogens that 
inevitably will be present in the food (Goldsby et al., 2003).  
There are also some soluble proteins, such as cytokines and other enzymes, which 
contribute to the immune system. A subgroup of cytokines is interferons (IFNs); these 
are primarily produced by virus-infected cells. They bind to the surface of 
neighbouring cells where they induce the production of antiviral proteins. These 
proteins stops the reproduction of viral elements in the cells, and thus limit the 
infection (VanPutte et al., 2013).  
Another group of proteins contributing to the innate defence is the complement 
system, which is a group of serum proteins circulating in peripheral blood and lymph 
fluid, in an inactive state. The proteins interact with bacteria, or cells invaded by a 
virus. This interaction can cause lysis of the cell or bacteria. In the innate immune 
system, the complement system promotes phagocytosis, stimulates the release and 
activation of other chemical mediators, and attracts the cells of the innate immune 
system (Goldsby et al., 2003; VanPutte et al., 2013). Phagocytosis is the ingestion and 
digestion of both exogenous antigens and endogenous matter. Exogenous antigens are 
pathogens and insoluble particles, endogenous matter is injured or dead host cells, 
cellular debris, and activated clotting factors (Goldsby et al., 2003). 
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Figure 1 shows the development of immune cells for both the innate and adaptive immune system. All the 
immune cells in the innate immune system are derived from a myeloid progenitor, which differentiate to a 
granulocyte/macrophage progenitor, which differentiate into the different cells. 
The adaptive immune cells are derived from a lymphoid progenitor, which can differentiate into a B- or a 
T-cell, which can develop into specialized B- and T-cells (Janeway, Travers, Walport, & Shlomchik, 2001).  
Besides the barrier defence and non-cellular defences described above, the innate 
immune system also contains a cellular defence. This defence consists of several 
different types of leukocytes, which are a specific group of blood cells. They can be 
separated into two subcategories; mononuclear leukocytes and polymorphonuclear 
leukocytes (Klein, 1991). These different cells can be seen in Figure 1. 
Monocytes are phagocytizing cells, and belong to the mononuclear subcategory. 
These cells can differentiate into macrophages or dendritic cells (DCs). The 
monocytes are produced in the bone marrow and are differentiated from a myeloid 
progenitor cell, seen in Figure 1.  
When the monocytes are fully matured in the bone marrow, they enter the blood 
stream and are thus spread to the rest of the body.  
Some monocytes leave the blood vessels and enter the tissue under the free surfaces 
of the body, this includes beneath the skin, mucous membranes and around blood and 
lymphatic vessels as well as lymphoid organs such as the liver, spleen, and lymph 
nodes. In these areas the monocytes differentiate into macrophages, which capture 
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and phagocytize pathogens. The monocytes entering the lymphoid organs usually 
send out dendrites and differentiate to dendritic cells (VanPutte et al., 2013).  
The DCs are strategically positioned in the lymphoid organs where the pathogens are 
transported. They have been transported by the blood or lymph to these organs and 
are gathered here to be phagocytized by cells such as macrophages, DCs, and 
neutrophils (VanPutte et al., 2013). 
During phagocytosis macrophages adhere to a bacteria covered by antibodies. The Fc 
receptors on the surface of the macrophage bind to the antibodies. The bigger the 
molecule, the more antibodies bind. This makes it easier for the macrophage to bind 
the invading pathogen.  
When bacteria are bound by a macrophage it induces a response, where membrane 
protrusions extend around the antigen-antibody complex and create a phagosome 
(Goldsby et al., 2003). The phagosome moves towards the interior of the cell, where it 
fuses with a lysosome, and becomes a phagolysosome, as seen in Figure 2. 
Lysosomes contain lysozyme and a variety of other hydrolytic enzymes. The content 
of the phagolysosome is digested, and degraded (Goldsby et al., 2003).  
 
Figure 2 shows how the macrophage phagocytise a pathogen, and how the activated macrophage afterwards 
presents the antigen to the immune system in an antigen-MHC class II complex. The pathogen is digested 
into its components and then the antigen is transported to the antigen presenting molecules, the MHC class 
II, on the surface (Goldsby et al., 2003; Russell, Vanderven, Glennie, Mwandumba, & Heyderman, 2009). 
Since the macrophage is also an antigen-presenting cell (APC), the antigens from the 
bacterial membrane surface are preserved. They are shown in combination with the 
major histocompatibility complex (MHC) II found on the macrophage cell membrane. 
The MHC will be elaborated in the adaptive immune system. The macrophages 
cooperate with the adaptive immune system by presenting antigens to T-cells 
(Goldsby et al., 2003; VanPutte et al., 2013). 
 
The macrophages have pattern recognition receptors (PRR) on their cell surface; this 
makes them able to recognize larger more general structures of the invading 
pathogens.  Some of these receptors are the Toll-like receptors (TLR), some of which 
are important in the recognition of patterns found on bacteria. When bacteria bind to a 
TLR a signal causes a transcript activation and secretion of cytokines that can attract 
other macrophages to the site of infection. This process, called chemotaxis, can also 
occur as a response to the complement system. When the macrophage reaches the site 
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of infection they can recognize the structural motif of the invading pathogen, which 
triggers phagocytosis and further secretion of cytokines (Goldsby et al., 2003).   
If the phagocytized material is indigestible, the macrophages regurgitate their content 
to the surrounding. Regurgitation also occurs when the macrophage is full.  
The other kind of leukocytes in the innate immune system is the polymorphonuclear 
cells seen in Figure 1, which have a different structure, since they contain more 
granules inside the cell. A granule is a vesicle, which contains enzymes and other 
immune molecules (Goldsby et al., 2003).  
The neutrophils are blood cells, produced in the bone marrow. When mature they 
circulate for 7-10 hours before they adhere to capillary walls. Here they find a 
junction between two epithelial cells, where they penetrate the vascular basement 
membrane and migrate to infected tissue, by a process called extravasation (Goldsby 
et al., 2003). Like the macrophages the neutrophil are phagocytizing cells. The 
neutrophils arrive faster to the site of infection and initiate the phagocytosis. Unlike 
the macrophage, the neutrophil cannot regurgitate and instead they die when it has 
reached its limit for the amount it is capable of phagocytizing (Goldsby et al., 2003).  
 
Basophils are the only cell in the innate immune system unable to phagocytise. They 
have a different effect. Their granules contain histamine and leukotrines, and these 
chemicals produce an inflammatory response and act in allergic responses (Goldsby et 
al., 2003; VanPutte et al., 2013).  
 
Eosinophils travel to the connective tissue when matured in the bone marrow with a 
primary function in defence against invading parasites. They spill the content of their 
granules onto the larger parasites, which kills the parasite by damaging their 
membrane (VanPutte et al., 2013). Although it is not their primary function, the 
eosinophils have some phagocytic abilities, but they are negligible compared to the 
neutrophils and the macrophages (Goldsby et al., 2003).  
 
Natural Killer (NK) cells are the only cells in the innate immune system derived from 
a lymphoid progenitor instead of a myeloid progenitor, which is seen in Figure 1. The 
NK cells are large granular lymphocytes that circulate in the blood and the lymph. 
These cells are important in the defence against tumour cells and some virus infected 
cells due to their cytotoxic activity (Goldsby et al., 2003). The NK cells are able to 
recognize target cells in two different ways. They can utilize some NK cell receptors 
used to detect abnormalities. This could be a reduction in MHC class I molecules 
present on the membrane surface. They can also detect an unusual profile of surface 
antigens found on some virus infected cells. 
The recognition of a virus infection, can lead to a production of antibodies, which 
binds to the antigens on the cell surface. The NK cells express CD16 on their 
membrane surface, and this receptor can attach to the antibodies by the process of 
antibody-dependent cell mediated cytotoxity. This process causes the destruction of 
the infected cell by lysis. When the NK cell is activated it releases lytic enzymes at 
the site of the infected cell, causing necrosis (Goldsby et al., 2003).  
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Opposing signals regulate the activation of NK cells; receptors on the NK cell surface 
have either an inhibitory or activating effect on the cell. These receptors are 
stimulated simultaneously and depending on which signal is the dominant, NK cells 
will recognize the other cell as healthy or infected, and the infected cell will be killed 
(Goldsby et al., 2003). 
Adaptive immunity 
The adaptive immunity is the second respond of the immune system. Unlike innate 
immunity, which reacts the same way when it comes in contact with a pathogen, 
adaptive immunity is able to remember the pathogens it has been in contact with 
before (VanPutte et al., 2013). This is due to memory B- and T-cells that are stored in 
the body after an infection. If the same infection happens, the memory cells can 
quickly reproduce and create a stronger and faster response. The adaptive immune 
system develops throughout a person’s life, as more memory cells are produced 
(Janeway et al., 2001). 
 
Adaptive immunity is stimulated by antigens, which are macromolecules that can 
elicit antibody production. They are presented on APCs. Foreign proteins are the most 
common and effective antigens, because the presence of foreign proteins in the body, 
results in the strongest response from the immune system. An antigen can also be a 
carbohydrate, most often a polysaccharide, or a lipid. The designation, antigens, 
comes from their ability to generate antibodies (Janeway et al., 2001). They are 
divided into two groups: foreign antigens and auto-antigens. Foreign antigens are 
found outside the body, and include bacteria, viruses, and other pathogens. Auto-
antigens are produced by the body. Autoimmune diseases occurs when the auto-
antigen stimulate an immune response that leads to tissue destruction (VanPutte et al., 
2013).  
 
A response to an antigen is either antibody-mediated or cell-mediated. An antibody-
mediated response involves B-cells and their production of antibodies; and cell-
mediated response involves T-cells (VanPutte et al., 2013). Both B- and T-cells are 
lymphocytes, or more specifically a type of mononuclear leukocytes. T-cells differ 
from B-cells and other lymphocytes by the presence of a T-cell receptor (TCR) on 
their surface. B- and T-cells are derived from precursor cells, and develop into mature 
B- and T-cells in the bone marrow and thymus respectively, as seen in Figure 3 on the 
following page.  
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Figure 3 shows how the B- and T-cells originate from a stem cell in the red bone marrow and then develop 
into a pre cell before processing to a mature B- and T-cell. This process takes place in the red bone marrow 
for B-cells and in the thymus for T-cells. They then enter circulation and later the lymph node where they 
will proliferate if an infection happens (VanPutte et al., 2013).  
The development of T-cells is more complex than the development of B-cells due to 
T-cells having a bigger variety of receptors and having two distinct lines of 
development. In most cases the first stages of development are similar for the B- and 
T-cells. The development takes place in multiple stages, each of which is marked by a 
rearrangement of the antigen-receptor genes and the expression of their protein 
products. For B-cells it is the immunoglobins (Igs) that need to be rearranged and for 
the T-cells it is TCRs (Janeway et al., 2001). The B-cells will be described later in this 
section. The TCR consists, in 95% of the cases, of an α- and a β-chain each of which 
is encoded by two genes. Both chains are composed of two regions, a variable region 
and a constant region as seen in Figure 3.  
 
 
Figure 4 shows a T-cell receptor. The T-cell receptor consists of a variable and a constant region. The 
constant region being closest to the cell membrane and the variable region closest to the antigen-binding site 
(VanPutte et al., 2013).  
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Once the rearrangement has taken place, the protein product is expressed on the cell 
surface where it functions as a signal, which allows the development to continue. The 
cells are still considered precursors once the rearrangement is completed and the 
antigen receptors have developed. A process called positive selection takes place in 
order to select the pre-B- and pre-T-cells that are capable of an immune response 
(VanPutte et al., 2013). Positive selection is a process that deselects the lymphocytes 
that bind either too strongly or too weakly to the antigen presented by MHC class I 
and II molecules and sends a survival signal to the cells that bind intermediately. It is 
only the cells that bind neither too strongly nor too weakly that get to survive, because 
they are beneficial for the immune system (Janeway et al., 2001). If the lymphocytes 
cannot bind to the antigen it would be a problem during infections. The process of 
negative selection is the deselection of auto-reactive lymphocytes because they could 
cause autoimmunity when they bind to the auto-antigens. As a result they receive an 
apoptotic signal which terminates them. It is consequently only a small portion of the 
lymphocytes that fully develop (Janeway et al., 2001). It is not all of the deselected 
auto-antigen reacting lymphocytes that are terminated; some of them get to live as 
regulatory T-cells (T-regs). T-regs functions as a suppressor of immune responses by 
inhibiting the effect of T-cells by releasing cytokines. This inhibits the proliferation of 
the B- and T-cells (VanPutte et al., 2013). 
 
After this selection the lymphocytes are considered fully mature and functional, but 
they will not survive long if they are not exposed to weak engagement of their antigen 
receptors in the absence of their specific foreign antigen. This could for example be 
engagement with the same antigen that initiated the positive selection (Janeway et al., 
2001). During adult life, the production of new B-cells in the bone marrow continues, 
whereas the production of T-cells declines. The quantity of T-cells is instead 
maintained by the mature T-cells dividing (Janeway et al., 2001).  
 
When a lymphocyte recognizes and binds to its specific antigen, it is activated. The 
lymphocytes do not recognize an entire antigen, but instead epitopes. Epitopes are the 
immunologically active region of an antigen, and each antigen can have multiple 
epitopes (Goldsby et al., 2003). B-cells can recognize and bind to the epitope alone, 
but T-cells can only recognize epitopes, which are presented on APCs (VanPutte et 
al., 2013). This presentation involves a type of glycoprotein, the MHC molecules. The 
MHC molecules are found on the surface of APCs such as macrophages. The 
presentation of an antigen by a MHC molecule is the most typical kind of activation. 
The MHC molecules display the antigen on the outside of the cell, so the cells of the 
immune system can react to it (VanPutte et al., 2013). There are two classes of MHC 
molecules: class I and class II, which are shown on Figure 5, on the next page. The 
MHC molecules are genetically determined and differ between people. The structure 
and the genetics of the MHC molecules will be described in the section ‘Genetic 
susceptibility for autoimmune diseases’. 
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Figure 5 shows the two classes of MHC molecules found on antigen presenting cells (APCs). MHC class I 
molecules present to the T-cell receptor of CD8+ T-cells and MHC class II present an antigen to CD4+ T-
cells (Parham, 2009).  
MHC class I molecules are found on nucleated cells, such as APCs. They display 
antigens produced inside the cell on their surface. When viral proteins are broken 
down in the cytoplasm, they enter the rough endoplasmatic reticulum where they 
combine with the MHC class I molecules. MHC class I and the antigen from the 
degraded protein form a complex that can move through the Golgi apparatus and be 
presented on the outside of the cell surface. TCRs are then able to bind to the MHC 
class I/antigen complex as seen on Figure 5. This activates the CD8+ T-cell, which 
can then destroy the infected cells (VanPutte et al., 2013). This process, of displaying 
a MHC/antigen complex, can also take place with proteins produced by the body 
itself, so that it is auto-antigens that are forming a complex with MHC class I. Most 
often the immune system does not respond to these, due to an inhibition or because 
the lymphocytes that would have reacted with them, have been eliminated during 
selection.  
 
MHC class II molecules are only found on APCs. Foreign antigens are taken in by the 
cells through endocytosis, and are broken down into fragments. These fragments are 
captured inside vesicles in the cell, and are combined with vesicles from the Golgi 
apparatus containing MHC class II molecules. The content of the vesicles form a 
complex, which is presented on the surface of the cell. TCRs are also able to bind the 
MHC class II/antigen complex (VanPutte et al., 2013). Unlike the MHC class 
I/antigen complex, the MHC class II/antigen complex does not signal a need for 
destruction of its hosting cell. Instead MHC class II/antigen complex signals for a 
stimulation of other immune cells to respond to the antigen, which in the end will 
destroy the antigen. The MHC class I/antigen activates the CD8+ T-cells whereas the 
MHC class II/antigen complex signals the CD4+ T-cells as seen in Figure 5. Often it 
is not only the MHC molecule and antigen complex that stimulates the immune 
activity, but instead co-stimulation which is multiple signals to the immune system. 
This can either involve cytokines, surface molecules or both (VanPutte et al., 2013).  
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Before the T-cell binds to the antigen it is considered a naive T-cell, but once it is 
activated, it proliferates and differentiates into a cell that is capable of fighting the 
infection (Janeway et al., 2001). It is then considered a specific effector T-cell. All 
activated T-cells in the immune system are effector T-cells. It is vital that the 
lymphocytes increase in number after an infection, because the amount otherwise is 
too small to mount an effective response. CD4+ T-cells are the first to proliferate. 
Their specialized function is to activate other cells, such as macrophages, or to 
activate CD8+ T-cells. The CD4+ T-cells have a glycoprotein called CD4+ located on 
their surface, which makes it possible for them to bind to the MHC class II molecules. 
This in turn stimulates the proliferation of the CD4+ T-cells (VanPutte et al., 2013). 
Cytokines that release interleukin-1 (IL-1) also stimulate proliferation of CD4+ T-
cells by binding to the CD4+ T-cell. Th-1 and Th-2 is a subpopulation of the CD4+ T-
cells. Th-1 produces cytokines which support inflammation while Th-2 produces 
cytokines that has the opposite effect (Goldsby et al., 2003).  
 
Once the CD4+ T-cells have proliferated, they stimulate the activation of other 
effector T-cells. This is done by releasing interleukin-2 (IL-2), which stimulates the 
production of CD8+ T-cells and memory T-cells. Memory T-cells can provide a long 
lasting immunity and a secondary response. They are able to survive without residual 
antigen, unlike the naive T-cells that need an antigen to bind to, in order to survive. 
This means that memory T-cells are already available in the body if the same antigen 
causes an infection, then they only need to proliferate in order to fight the infection 
(Janeway et al., 2001). CD8+ T-cells have a glycoprotein on their surface called 
CD8+, which helps them bind to MHC class I molecules presenting antigens. The 
CD8+ T-cells can lyse the infected cell by releasing chemicals. One of these 
chemicals is the protein perforin. Perforin creates a channel through the membrane 
into the cell, through which water can travel causing the cell to lyse. Besides lysing, 
the other effect of the CD8+ T-cells is the production of cytokines. The cytokines are 
produced to activate additional components of the immune system to strengthen the 
response (VanPutte et al., 2013). 
 
The cell-mediated immunity, the effector T-cells, is most effective against 
intracellular microorganisms, unlike the B-cells which are most effective against 
extracellular microorganisms. This is due to the T-cells being able to destroy the cells 
in which the intracellular microorganisms are located (VanPutte et al., 2013). 
 
In order to not react and develop an immune response to auto-antigens the 
lymphocytes develop tolerance, which is an unresponsive state. There are two 
different types of tolerance: the central and periphery. The central tolerance is 
established in the bone marrow for B-cells and thymus for T-cells; it takes place 
during the maturation of the lymphocytes. It is designated central because the B- and 
T-cells develop tolerance toward those auto-antigens present in the primary lymphoid 
organs.  
 13 
The periphery tolerance on the other hand develops as the mature lymphocytes enter 
circulation and involves T-regs. It is a tolerance toward auto-antigens that are found 
elsewhere than the primary lymphoid organs (Janeway et al., 2001).  
 
Progenitor B-cells are found in the bone marrow where they develop, differentiate, 
and proliferate. When they begin to express IL-7 receptor molecules the progenitor B-
cells have developed into precursor B-cells (Goldsby et al., 2003).  
For the continued development and differentiation into naive B-cells, the cells have to 
express antibodies on their surface. An antibody is a Y-shaped molecule, called 
immunoglobulin (Ig), which consists of two heavy and two light chains that can be 
divided into different regions. The antigen-binding end of one heavy and one light 
chain is called the V-region, the rest of the molecule is called the C-region, which can 
be divided into subcategories as seen in Figure 6. The V-region is more variable, than 
the C-region, and the differences in this region account for the specificity of antigen 
binding (Janeway et al., 2001).  
 
 
Figure 6 shows two antigens. 6a shows an antigen with the light chains, coloured yellow, and the heavy 
chains, coloured green. 6b shows an antigen where the variable region is red, and the constant region is 
blue. An antigen can be divided up into either heavy and light chains, or into variable and constant regions 
(Janeway et al., 2001). 
The immunoglobulin has two identical heavy chains and two identical light chains, 
which means it has two identical antigen-binding sites.  
This rearrangement of genes coding for the immunoglobulin happens in very specific 
order; first the heavy chain is altered and the cell can now be classified as a precursor 
B-cell. Further development requires rearrangements in the light chain as well. When 
the light chain has developed and binds to the heavy chain, the antibody IgM is 
formed. When it is expressed on the surface of the precursor B-cell, it is said to be an 
immature B-cell (Janeway et al., 2001).  
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Figure 7 shows the development of B-cell from stem cell to a mature B-cell. After this development the B-
cell leave the bone marrow and can develop to a specialized B-cell. First the heavy chain develops, with 
rearrangement in the genes. When the heavy chain has been rearranged, the light chain starts gene 
rearrangement and when this is done, the B-cell begins to express IgM molecules on the cell surface. In the 
mature B-cell both IgM and IgD are expressed on the surface (Janeway et al., 2001). 
At this stage the further development is restricted by a selection for the B-cells 
expressing auto-antibodies, which react against the auto-antigens in the bone marrow. 
If the B-cell expresses auto-IgM the ability to bind to auto-antigens will cause the 
immature B-cell to undergo apoptosis.  
If the B-cells get past this test it is now an immature B-cell. To become a mature B-
cell the cell has to express both IgM and another antibody called IgD, the 
development can be seen in Figure 7 (Goldsby et al., 2003).  
After maturation the naive B-cells migrate from the bone marrow, ready to encounter 
the antigens in the body. This differentiation occurs in the spleen. The naive B-cells 
are transported to this site by the blood. At this site the antigens accumulate, which 
makes this an ideal place for the B-cells to mature (VanPutte et al., 2013).  
 
The activation of the B-cells happens when it proliferates and differentiates. This can 
occur by two different routes, the thymus dependent (TD) and the thymus 
independent (TI) (Goldsby et al., 2003).  
The TD response requires a CD4+ T-cell interaction, with a cell responding to the 
same antigen as the B-cell. The membrane bound CD40 ligand, is very important 
because it binds with the B-cell surface molecule, CD40. The CD4+ T-cell, more 
specifically the Th-2 cell, synthesizes IL-4 and secretes it near the binding site to the 
B-cell. The antigen specificity, the CD40/CD40L binding, and the secreted IL-4 
together leads the B-cell into proliferation and differentiation, as seen on Figure 8, on 
the following page. This differentiation leads to either memory B-cells or plasma cells 
(Goldsby et al., 2003; Janeway et al., 2001).  
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The TI response can be categorized into two different subcategories, type 1 (TI-1) and 
type 2 (TI-2). 
The TI-1 response is initiated by specific bacterial proteins, which are able to 
stimulate the B-cell without the presence of T-cells. These proteins are known as TI-1 
antigens and are able to directly initiate B-cell division, regardless of the antigen 
specificity. These cells do not differentiate into different cells, like the other response 
induces. In this response there is only produced plasma cells, with one specific 
antibody response (Goldsby et al., 2003; Janeway et al., 2001).  
The TI-2 response is initiated by TI-2 antigens, which are repetitive forms of the site 
of the antigen recognized by the B-cell. It has been shown that the total lack of T-cells 
eliminates the response in TI-2. It is unclear how specifically the T-cells influence the 
development, but it indicates that the B-cell requires cytokines secreted from the T-
cells to divide and differentiate into plasma cells (Janeway et al., 2001).  
 
 
Figure 8 shows the thymus independent I pathway and the thymus dependent pathway in the development 
and maturation of the B-cells. Figure 8a shows how the thymus independent pathway is only dependent on 
unspecific antigens, for initiating a response and development. Figure 8b on the other hand shows a thymus 
dependent pathway, relaying on a specific antigen presented by an active CD4+ T-cell, a binding between 
the two surface molecules CD40/CD40L, and interleukine 4 (IL-4) secretion from the specific T-cell 
(Janeway et al., 2001). 
The TI responses are generally weaker and, as mentioned, only allow the naive B-cell 
to differentiate into a plasma cell, which only produce IgM. The TD response, on the 
other hand, creates a lot of memory B-cells and plasma cells, which secrete IgM and 
are able to switch isotype and secrete IgD and some other types of antibodies as well. 
This pathway creates a much stronger response compared to the TI-response, but also 
a much slower response, due to the more extensive pathways involved.  
The major effect of the B-cells is to produce memory and plasma cells, which produce 
antibodies. These are important in activating other cells in the immune response, and 
ease the phagocytosis of foreign antigens (Goldsby et al., 2003). 
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Autoimmunity  
An autoimmune disease occurs when an adaptive immune response is mounted 
against auto-antigens. In such situations auto-antibodies and auto-reactive 
lymphocytes attack body tissue by activation of auto-antigen-specific immune cells 
from both the innate and the adaptive immune system. The immune cells respond to 
the auto-antigens like they were antigens derived from a foreign pathogen that needs 
to be eliminated because they otherwise cause tissue damage either directly or 
indirectly. As a result, the tissue where the auto-antigen is found is treated as a foreign 
tissue.  
It is in most cases impossible for immune effector mechanisms to eliminate the 
antigen completely, because the body provides a constant supply of new auto-
antigens. The immune responses are constantly triggered and amplified (Janeway et 
al., 2001). This constant immune response against auto-antigens can results in chronic 
inflammatory injury in the affected tissue (Agger, Nielsen, Leslie, & Aasted, 2012). 
The tissue damaging mechanisms in autoimmune diseases are essentially the same as 
those that operate in protective immunity and in hypersensitivity diseases, which can 
be mediated by the effector actions of both B- and T-cells (Janeway et al., 2001). 
When the functions and structures of tissue are damaged by the autoimmune response, 
autoimmune disorders or diseases appear. The exact mechanisms causing 
autoimmunity are not completely understood, and varies from disease to disease 
(Agger et al., 2012). Both environmental and genetic factors are said to cause 
autoimmunity. A genetic factor is MHC genotypes these are important, because 
autoimmune responses involve T-cells and the ability of T-cells to respond to a 
particular antigen depends on the properties of the MHC molecules (Janeway et al., 
2001). Environmental factors could be viruses and vitamin D (Schwalfenberg, 2012).  
 
Autoimmune diseases can be classified as either organ specific or systemic (Fridkis-
Hareli, 2008). Organ specific autoimmunity occurs when the autoimmune response is 
restricted to specific organs. Examples of organ specific autoimmune diseases are 
Hashimoto’s thyroiditid and Graves disease, each affecting the thyroid gland and MS, 
which affects the myelin sheaths in the CNS (Fridkis-Hareli, 2008). The systemic 
autoimmune diseases occur when multiple body tissues or cells found in the 
circulation are affected. Examples are systemic lupus erythematosus and primary 
Sjögren’s syndrome, in which tissues such as skin, kidneys, and the brain all can be 
affected simultaneously (Fridkis-Hareli, 2008). 
The organ specific autoimmune diseases frequently occur together in a lot of 
combinations. For example the autoimmune depigmenting disease Vitiligo and the 
autoimmune thyroid disease are often found in the same individual (Janeway et al., 
2001). Not all autoimmune diseases can be classified as either organ specific or 
systemic. Some diseases like haemolytic anemia and T1D can in some circumstances 
be both organ specific and systemic (Janeway et al., 2001). Conditions like these may 
be caused by multiple factors including immunology genetic and environmental 
(Fridkis-Hareli, 2008). 
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Genetic susceptibility for autoimmune diseases 
The properties of the MHC molecules are crucial for the pathogenesis of autoimmune 
diseases. MHC molecules are responsible for antigen presentation and the immune 
response is determined and initiated by the properties of the MHC found on APCs.  
The genes that encode the MHC molecules are located on the short arm of 
chromosome 6p21 as shown in Figure 9 (Link et al., 2012; Yeo et al., 2007). The 
genes are found in the HLA loci, and the designation is short for Human Leukocyte 
Antigen. It originates from the fact that the genes were first discovered through 
antigenic differences between white blood cells from different individuals (Cree, 
2014). These HLA loci contain about 400.000 base pairs, and encode more than 200 
genes. The study of the genes is not yet completed, and the numbers are likely to 
grow in line with further studies (Stankov, Benc, & Draskovic, 2013). 
 
 
Figure 9 shows the human chromosome 6p21 where the HLA genes are positioned on the short arm. Class I, 
II, and III HLA genes are shown. The loci coloured red, the HLA class II, encodes the MHC class II 
molecules. The regions coloured blue, the HLA class I, encodes the MHC class I molecules. The non-
designated blue lines indicate the additional HLA class I genes E, G, and F genes. The loci coloured green 
encodes the HLA class III genes, where TNF among others are encoded. Modified (Press, 2003). 
The loci encode three classes of genes, the class I-, II- and III-HLA genes (Field et al., 
2010; Muñoz-Culla, Irizar, & Otaegui, 2013; Yeo et al., 2007). Class I genes encode 
MHC I molecules and class II genes encode MHC II molecules. The class III genes 
encode some complement proteins, the cytokines tumor necrosis factor-α (TNF-α) 
and other immune related genes. MS and T1D genetic associations are only found in 
class I and II HLA genes (Janeway et al., 2001), therefore class III genes will not be 
discussed.   
 
There are eight molecules involved in antigen presentation. Three of those belongs to 
MHC class I molecules and five belongs to MHC class II molecules. The five MHC 
class II molecules are the DR, DQ, DP, DO, and DM molecules. DR, DQ, DP are 
found external on the APC. DO and DM are involved in the internal process of 
antigen presentation and their function is to load the peptides produced from the 
antigen to the MHC class II molecule on the external site of the APC.  Each of these 
five molecules is formed by an α- and a β-subunit or chain, as seen in Figure 10, each 
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encoded by a single gene. The genes that encode the α-subunits contain an A in their 
gene name, for example HLA-DQA1, and likewise a B for the β-subunit. In order to 
form a MHC molecule the complementary α- and β-subunit have to bind together, for 
example the α-subunit encoded by HLA-DQA1 has to form a complex with the β-
subunit encoded by HLA-DQB1. For HLA-DRB four genes encode different β-
subunits: HLA-DRB1, -DRB3, -DRB4 and -DRB5 (Janeway et al., 2001).  
There are three genes that encode MHC class I molecules HLA-A, HLA-B, and HLA-
C. The MHC class I molecules are not formed by subunits, but are instead formed by 
a single protein encoded in a single gene. The β-microglobulin, which is shown on 
Figure 10, does not vary and is a part of MHC class I. The gene encoding β-
microglobulin is found on a different chromosome, and is therefore not part of the 
genetic susceptibility, for MS and T1D, found in the HLA region (Janeway et al., 
2001). 
 
Figure 10 shows a MHC class I and II molecule. The MHC class I molecule is formed by an α-subunit and 
the invariable β-microglobulin. The MHC class II molecule is formed by an α-subunit and β-subunit 
Modified (Crispr, 2013). 
The HLA genes are highly polymorphic, which means that more than one allele can 
be found in each gene locus. For the HLA class I genes there are 2735 different HLA-
A alleles, 3455 HLA-B alleles, and 2259 HLA-C alleles. 
In the HLA class II genes, the number of alleles is greater due to the different α- and 
β-subunit or chains. The numbers of HLA class II alleles are shown in Table 1 on the 
following page.  
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Table 1 shows the number of alleles for the different HLA class II genes and the number of possible 
combinations between the α- and β-subunit. The numbers of alleles are high which indicate the high 
polymorphic properties of these genes. This results in a great variance of MHC class II between individuals 
(Robinson et al., 2013).  
 
 A1 B1 B3,4,5 Number of  
possible combinations 
HLA-DP 38 alleles 344 alleles   13,072 
HLA-DQ 52 alleles 594 alleles   30,888 
HLA-DR 7 alleles 1468 alleles 93 alleles  10,927 
HLA-DM 7 alleles 13 alleles   91 
HLA-DO 12 alleles 13 alleles   156 
 
Each of these alleles can be given a specific name according to the nomenclature 
valid for the HLA region. As an example a common allele combination found in 
autoimmunity is DQA1*0301, DQB1*0302 that together form a molecule called 
DQ8. This means that the α-subunit subunit is encoded by allele number 0301, found 
in the DQA1 locus and the β-subunit is encoded by allele number 0302, found in the 
DQB1 locus. The term DQ8 is called a serotype. A serotype of a MHC molecule 
covers more than one α and β allele. A serotype contains those alleles that are so alike 
that they do not vary in the regions that are recognised by the antigens. In other words 
the different alleles assigned to a single serotype do not vary in function even though 
the alleles vary in DNA sequence. The term DQ8 is thus a broader genetic term that 
covers a number of different alleles, which do not vary in antigen presenting function. 
HLA molecules also have a number of serotypes, each described with a number 
reaching from 1 to 50 (Klitz et al., 2003). 
 
The presence of different alleles of each MHC class means that different individuals 
are able to present a broad range of peptides. This variance is so great that only few 
individuals have identical alleles and the total amount of different proteins encoded 
by the HLA genes are practically unique in every person. Much fewer serotypes exist 
than alleles therefore many people share the same serotype. This makes it easier to 
handle the large variation in HLA genes, which provides a challenge when the role of 
these are to be studied in different diseases (Janeway et al., 2001). 
 
The MHC molecules are used by the immune system to differentiate between 
molecules, peptides, cells belonging to the body, and foreign cells. The cell therefore 
has to express MHC molecules that can be recognized, as belonging to the body, 
otherwise the immune system will create an immune response that target the cell.  
In most cases the genetic susceptibility for autoimmune diseases is found in the class 
II HLA genes, because MHC class II molecules can initiate a CD4+ T-cell mediated 
immune response, that result in activation of CD8+ T-cells and memory T-cells. This 
activation makes the response more complex and longer lasting than an immune 
response mediated only by CD8+ T-cell (Janeway et al., 2001).    
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The different MHC molecules encoded by different alleles posses different abilities in 
their presentation of antigens (Janeway et al., 2001). The alleles encoding the MHC 
molecules determine which antigens the cells are able to present (Richardson, 
Willcox, Bone, Morgan, & Foulis, 2011). If the MHC molecules are encoded by 
certain alleles they will be able to present antigens, which the MHC molecules should 
not normally present. MHC molecules also posses different abilities in presenting an 
auto-antigen for auto-reactive immune cells because not every MHC molecule is able 
to bind to the auto-antigen. The immune system will in this case respond by treating 
the APCs showing these MHCs as foreign, this will induce an immune response 
against the auto antigen presenting cells. When the APC is an immune cell, the 
immune response will not result in the destruction of the APC. When the APC is not 
an immune cell, the immune response will result in the destruction of the cell carrying 
the MHC (Janeway et al., 2001). Depending on the MHC alleles, an individual’s 
susceptibility for developing an autoimmune disease differs.  
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Vitamin D  
Many epidemiologic studies have suggested that exposure to sunlight is important in 
preventing many chronic diseases, because it enhances the production of vitamin D3 
in the skin. Vitamin D is a group of fat-soluble steroid hormones found in many 
forms. The classic role of vitamin D is to regulate calcium homeostasis. The two 
major physiologically relevant forms are vitamin D2, and vitamin D3. Most humans 
obtain vitamin D through diet, such as oils, enriched milk, eggs, and supplements. 
Pre-vitamin D is converted by sunlight to vitamin D3 in the skin (Holick F Michael, 
2004; VanPutte et al., 2013).  
Sufficient amounts of vitamin D3 are produced in the skin during spring, summer, and 
fall, when there is enough sunlight present to enable vitamin D3 to be stored in the 
body fat. During the winter months, when just a small amount of Vitamin D3 is 
produced the body may use the vitamin D3 that is stored. When a person becomes 
vitamin D3 deficient, there is a decrease in the efficiency of intestinal calcium 
absorption (Holick F Michael, 2004). During the exposure to sunlight, ultraviolet B 
radiation (UVB) is absorbed by 7-dehydrocholesterol and vitamin D3 is produced, 
which is seen in Figure 11. The absorption takes place in the plasma membranes of 
both epidermal keratinocytes and dermal fibroblasts. The absorption of this radiation 
results in a transformation process, in which vitamin D3 is released from the plasma 
membrane into the extracellular space (Holick F Michael, 2004; Pierrot-Deseilligny & 
Souberbielle, 2013).  
 
Figure 11 shows the first steps of vitamin D metabolism. 7-dehydrocholesterol is converted into vitamin D3 
in the skin through ultraviolet B radiation from the sun or from oral intake.  Through the bloodstream 
vitamin D3 is transported by vitamin D binding protein and hydroxylated in the liver. In the second step, 
pre-vitamin D3 is converted to calcitriol, which takes place in the kidney and elsewhere (Wolden-Kirk et al., 
2011). 
The vitamin D binding protein (DBP) in dermal capillary bed has an affinity for 
vitamin D3 and pulls it into the blood circulation where vitamin D is transported in the 
bloodstream by DBP and protein albumin to the liver (Christakos, Ajibade, Dhawan, 
Fechner, & Mady, 2010; Holick F Michael, 2004). 
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In the liver vitamin D3 is hydroxylated and catalysed by several vitamin D-25-
hydroxylase enzymes, which hydrolyze vitamin D3 to hydroxyvitamin D (25-OH-D). 
The active metabolite of vitamin D is the steroid hormone, calcitriol. This hormone is 
the result of the second hydroxylation, which takes place in the proximal tubule of the 
kidney, and is catalysed by the enzyme 1α-hydroxylase, encoded by the gene 
CYP27B1 (Pierrot-Deseilligny & Souberbielle, 2013). Vitamin D-24-hydroxylase is 
another enzyme that is localized in the renal tubule, and encoded by the gene 
CYP24A1, which is capable of inducing an inactivating path for vitamin D 
metabolites (Pierrot-Deseilligny & Souberbielle, 2013). 
A study shows that, when there is a low intake of calcium it results in the parathyroid 
hormones to stimulate renal hydroxylation, which in turn results in an increase of the 
calcitriol level in the blood (Pierrot-Deseilligny & Souberbielle, 2013).  
When calcitriol enters the target cell, it dissociates from DBP and binds to a specific 
vitamin D receptor (VDR) within the cytoplasm and forms a complex. When the 
complex enters the nucleus, it forms a heterodimer, calcitriol-VDR-RXR, by 
connecting the complex to a nuclear receptor called retinoid X receptor (RXR) 
(Pierrot-Deseilligny & Souberbielle, 2013). 
The heterodimer then binds to vitamin D-responsive elements (VDREs), which 
comprise a specific DNA sequence within the promoter region in the target genes. 
The final result is gene transcription regulation seen in Fejl! Henvisningskilden blev 
ikke fundet. (Pierrot-Deseilligny & Souberbielle, 2013).  
 
 
Figure 12 shows vitamin D metabolism. When UVB is absorbed in the skin or when vitamin D is taken as a 
supplement, 7-dehydrocholesterol is transferred into vitamin D3 and is transported through the 
bloodstream to the liver by vitamin D3 binding protein (DBP). By hydroxylations vitamin D is converted to 
calcitriol, which is the finale metabolite in vitamin D metabolism. When calcitriol enters the cell it 
dissociates from DBP and binds to vitamin D receptor (VDR) in the cytoplasm. Then the complex enters the 
nucleus and forms a heterodimer, which binds to vitamin D responsive elements (VDREs). This attachment 
comprises a specific DNA sequence in the target genes and results in regulation of gene transcription 
(Pierrot-Deseilligny & Souberbielle, 2013). 
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Multiple Sclerosis 
MS is an autoimmune disease where the CNS is attacked by the immune system. The 
attacks against the CNS appear as physical, mental, and cognitive symptoms. The 
most recognizable symptoms are weakness, sensory disturbance, reduced strength and 
numbness in legs and arms, and reduced vision. These symptoms are often the first 
signs of MS, and can be followed by additional symptoms. The symptoms differs 
among individuals and can vary from time to time, which characterizes the disease 
(Scleroseforeningen, 2013b). There are different classes of MS and the progression in 
each class is often seen as relapses, and is expressed as the symptoms mentioned 
above. The relapses occur in periods and makes the neurological functions worse, and 
is sometimes followed by a recovery period where these relapses can disappear 
completely (National Multiple Sclerosis Society, 2014b; Scleroseforeningen, 2013b). 
The neurological functions are directly damaged because of the autoimmune reaction 
against the myelin sheaths. There are four classes of MS: relapsing remitting (RR), 
primary progressive (PP), secondary progressive (SP) and progressive relapsing (PR) 
and the classes are diagnosed differently among individuals (Mayo, Quintana, & 
Weiner, 2012; National Multiple Sclerosis Society, 2014b; Scleroseforeningen, 
2013b). MS patients can experience more than one class during the course of their 
disease (National Multiple Sclerosis Society, 2014b).  
In the RR class new symptoms appear and last from days to months, or already 
existing symptoms get worse. The relapses then disappear partially or completely and 
the disease do not progress any further which is seen in Figure 13. 85% of all MS 
patients are often first diagnosed with the RR class. PP is the class where MS starts to 
develop gradually, sometimes over years with gradual loss of disability as seen in 
Figure 14. 10% of the people affected with MS have PP. About 50% of MS patients 
start with RR, and end up with SP, which causes smaller progression, but sometimes a 
more quick development of the disease as seen in Figure 15. The last type is PR, 
which are the least common type of MS and are slowly developing with a little or no 
recovery after relapses, which are seen in Figure 16 (Mayo et al., 2012; National 
Multiple Sclerosis Society, 2014b; Scleroseforeningen, 2013b).  
 
 
Figure 13 shows relapsing remitting MS (RRMS), which is the most common form of MS and are defined as 
relapses and aggravation of the neurological functions. The relapses are seen as elevations on the graph and 
are sometimes followed by a complete period without symptoms (National Multiple Sclerosis Society, 
2014b). 
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Figure 14 shows primary progressive MS (PPMS), which is shown as a gradually aggravation of 
neurological functions, but no relapses. This form of MS sometimes has small improvements over time 
(National Multiple Sclerosis Society, 2014b). 
  
 
Figure 15 show secondary progressive MS (SPMS) and is characterized by a progress after the relapses. 
This type of MS is often a follow-up from the RR type, which mean that its progression slows down over 
time (National Multiple Sclerosis Society, 2014b). 
 
 
Figure 16 shows progressive relapsing MS (PRMS) and is the least common type of the disease. It is 
characterized by sometimes a little, sometimes non recovery after the relapses (National Multiple Sclerosis 
Society, 2014b).  
Most knowledge about MS is obtained from studies in animal models of the disease 
called experimental autoimmune encephalomyelitis (EAE). This model has provided 
information about the roles of the adaptive and innate immune system (Hartung, 
Aktas, Menge, & Kieseier, 2014). The EAE model is based on mouse and rat strains, 
and also used in preclinical research and among other things, to test side effects on 
different kinds of drugs for MS treatment ( ’t Hart, Gran, & Weissert, 2011).  
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In preclinical research, mice or rats are induced with inflammatory demyelinating 
syndrome by active immunization with myelin proteins, which will result in an 
immune response. The goal in this research is to investigate this immune response in 
the myelin sheaths, which is seen as interrupted nerve impulses through the spinal 
cord, or plaques in the CNS (Segal, 2003). These results in the EAE models are not 
completely compatible with humans. One reason for this is that humans and mice 
have immunological differences in both the innate and adaptive immune system ( ’t 
Hart et al., 2011).   
The cause of MS is still not completely known. What is known is that the innate and 
adaptive immune system both play a role in the disease and that the white and grey 
matter in the CNS is affected (Gaby, 2013; Hartung et al., 2014). The grey matter 
consists of nerve cell bodies and axons, while the white matter consists of the myelin 
sheaths surrounding them. The plaques in the white matter are formed because of the 
demyelination (Hartung et al., 2014). 
Myelin is formed by oligodendrocytes cells and is surrounded by astrocytes. The 
plaques occur, due to the demyelination, axonal inflammation, destruction of 
oligodendrocytes cells, and a negative proliferation of astrocytes (Perkin, George D 
Wolinsky, 2006). In some cases these infection attacks causes lifelong loss of myelin. 
In other cases oligodendrocyte molecules remyelinate the myelin around the axons, 
but the demyelination will eventually lead to neurological dysfunction (Perkin, 
George D Wolinsky, 2006).  
 
The immune response in MS is driven by several different adaptive immune cells, 
which target specific myelin auto-antigens in the CNS, this process is shown in Figure 
17, on the next page. Myelin auto-reactive T-cells are observed in the peripheral 
blood of both healthy people and in MS patients.  The T-cells found in MS patients 
are activated and have developed memory phenotype, whereas the T-cells found in 
healthy people are naive T-cells (Lovett-Racke et al., 1998). The myelin specific T-
cells and the memory T-cells, found in MS patients, mature and are activated outside 
the CNS. In the peripheral blood the T-cells are activated by APCs that are thought to 
present antigens that mimics the myelin auto-antigens and this presentation results in 
development of myelin specific T-cells (Baranzini & Hauser, 2002). Before these 
myelin specific T-cells in the peripheral blood can react directly on myelin in CNS 
they have to pass either the blood brain barrier (BBB) or blood-cerebrospinal fluid 
(CSF) barrier whose function are to protect the CNS. The BBB is the main structure 
protecting the part of CNS located in the brain; it acts as a highly protecting barrier 
that only allows very few substances to access the brain. A similar barrier called the 
blood-CSF barrier protects the part of the CNS located in the spinal cord. The blood-
CSF barrier provides a segregation of the peripheral blood and spinal fluid. When the 
MS plaques are found in the spinal cord, and the demyelination happens in that part of 
the CNS, the immune cell migrate pass this barrier (Holman, Klein, & Ransohoff, 
2011). Myelin specific T-cells are under normal circumstances not tolerated in the 
CNS and are blocked from entering the CNS by the BBB and the blood-CSF barrier. 
The BBB is formed by tight-junctions between the capillary endothelial cells. The 
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astrocytes form these tight-junction and they form a thin membrane structure that 
surrounds the endothelial cells, and creates the support needed for the BBB structure 
(VanPutte et al., 2013).  
 
 
Figure 17 shows the immune response against myelin sheaths in MS. (1) shows how the naive T-cells in the 
peripheral blood are activated by antigen presenting cells (APCs) that present antigens which are thought 
to mimic myelin antigens (Baranzini & Hauser, 2002). (2) shows how the activated T-cells are then guided to 
the blood brain barrier (BBB) by the chemokine gradient. The T-cells express adhesion molecules that bind 
to adhesion molecules on the endothelial cells of the BBB. Facilitated by the chemokine gradient and 
adhesion molecules the T-cells migrate through the BBB. (3) shows how once the T-cells have migrated 
through the BBB they are reactivated by APCs in the CNS that present actual myelin antigens. In (4) this 
reactivation leads to the release of cytokines and chemokines, which facilitate the recruitment of 
macrophages and B-cells. The B-cells develop plasma cells that form antibodies against myelin antigens. (5 
+ 6) shows how this immune response leads to demyelization and axon damage (Hohlfeld, 2009).   
When the endothelia cells are exposed to TNF-α secreted by macrophages and T-cells 
it induces the expression of adhesion molecules. These molecules bind tightly to 
integrins on the T-cells, and thereby facilitate the migration of T-cells through the 
tight-junctions in the endothelium. Integrins are cell surface proteins expressed on the 
T-cells. The integrins binds to adhesion molecules on the endothelial cells. By 
binding to adhesion molecules on the BBB integrins mediate adhesion between the 
BBB and T-cells. The ability of T-cells to pass through the BBB is further due to a 
chemokine gradient that attracts the T-cells to the endothelium of the BBB. The 
chemokine gradient is formed by increased amounts of immobilized chemokines, 
which are expressed in high amounts in the CNS. The chemokines are secreted by 
immune cells inside the CNS; they then migrate to the endothelium where they 
accumulate. In this way some of these chemokines can be found on the periheral side 
of the endothelium where they are immobilized. The fact that the chemokines are 
immobilized means that they are bound to the endothelium of the BBB. The 
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immobilized chemokines captures immune cells from the blood passing the BBB as 
seen in Figure 18 (Janeway et al., 2001). The chemokine receptors are transmembrane 
G-coupled receptors. When these receptors are activated, integrins receive a signal 
that courses them to change conformation. This new conformation enables them to 
bind tightly to their ligand on the endothelium. The receptor binding results in an 
increased binding affinity for integrins and a clustering of integrins on the surface of 
the T-cells (Holman et al., 2011). The chemokines only attract specific immune cells 
and the type of chemokines present therefore determines which immune cells will be 
recruited and migrate to the CNS (Holman et al., 2011). Chemokines thus induce the 
directional migration and activation of B- and T-cell immune reactions, and they also 
regulate cell adhesion molecules (Charo & Ransohoff, 2006). MS patients show an 
upregulation of the adhesion molecules, which interact with T-cells. This upregulation 
makes it more likely that the activated T-cells interact with the BBB and initiates an 
inflammatory response in the CNS (Comabella & Khoury, 2012). The migration 
process facilitated by adhesion molecules, integrins and chemokines are shown on  
Figure 18. 
 
 
 
Figure 18 shows how the immune cells are recruited to the endothelial of the blood brain barrier (BBB) by a 
chemokine gradient and adhesion molecules. On the figure the adhesion molecules are designated E-selectin 
and ICAM-1. The E-selctins initiates the T-cell endothelial interaction, but this interaction is not strong 
enough to arrest the T-cells. The arrest of the T-cells is due to the subsequent binding to ICAM-1. The 
additional properties and action of these specific adhesion molecules will not be further discussed. The 
cytokine TNF-α  released by macrophages induce the expression of adhesion molecules, ICAM-1’s, in the 
endothelial cells. These adhesions molecules bind to integrins on the T-cells. On the figure the integrin is 
designated LFA-1(αL:βL). Binding between the chemokine receptors, in this figure IL-8 receptor, on the T-
cells and chemokines, chemokine IL-8, induces the expression of integrins. This provide a tight binding that 
arrest the T-cells. This allows the T-cells to pass through the tight junctions between the endothelial cells. 
The action of the MMPs and other BBB degrading enzymes are not shown in this figure. Modified (Janeway 
et al., 2001) 
The activated T-cells that have entered the CNS recruit other immune cells from the 
peripheral blood, which also act specifically against the myelin sheaths. The T-cells in 
the CNS activate B-cells and plasma cells by the release of chemokines. The B-cells 
and plasma cells therefore migrate from the peripheral blood to the CNS (Hartung et 
al., 2014).  
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The immune cells inside the CNS also recruit other immune cells from the peripheral 
blood through the release of chemokines. Additional to the chemokine gradient the 
immune cells are recruited because the blood vessels surrounding the inflammation 
site are dilated. This dilation allows a slower blood flow and thereby permits the 
immune cells to move out of the center of the blood vessel and reach the endothelium. 
In the endothelium the adhesion molecules are induced by the immune response, in 
particular TNF-α.  The binding to chemokines also induces the adhesion molecules 
on the immune cells. This induction leads to the recruitment of a large number of 
immune cells from the peripheral blood. Once these immune cells reach the site of 
infection the process, shown in Figure 18, begins and the immune cells thus migrate 
through the endothelia cells of the BBB and into the CNS (Janeway et al., 2001).  
 
An additional factor that contributes to the migration through the BBB is a subgroup 
of the CD4+ T-cells, called Th-17 cells. The Th-17 cells secrete cytokines that 
facilitate the disruption of the BBB and migration of CD4+ T-cells to the CNS, and in 
this way contributes to mediate the immune response in MS (Kebir et al., 2007). Th-
17 cells release the pro-inflammatory cytokine IL-17, which provides an efficient 
migration of the immune cells through the BBB (Kebir et al., 2007).This is due to IL-
17 binding to IL-17 receptors present on the endothelial cells in the human BBB. The 
binding of these cytokines to their receptor makes it possible for the cytokines to bind 
to the endothelial cells and break through the tight junctions in the BBB. The Th-17 
cells also secrete IL-22, receptors for IL-22 are also found on the BBB. The IL-22 and 
IL-17 cytokines also recruit additional CD4+ T-cells (Kebir et al., 2007). The same is 
shown for TNF-γ released by Th-1 cells (Kebir et al., 2009).  
IFN-γ upregulates MHC class I and II in many cell types, promotes Th-1 
differentiation and activates macrophages (Freiesleben et al., 2010). These cytokines 
are thus a contributing factor in CNS immune infiltration and the immune response. A 
high amount of IL-17 makes the BBB more permeable and the secretion of other pro-
inflammatory cytokines makes the Th-17 cell an important mediator of the 
autoimmune response in MS. Th-17 cells can migrate efficiently through cells in the 
BBB. This could be due to the fact that Th-17 cells have a cytolytic effect, provided 
by the secretion of granzyme B. Granzymes are serine proteases and their role is to 
induce apoptosis in target cells. One of the multiple ways Granzyme B can induce 
apotosis is this: Once released by the cytotoxic T-cells granzyme B binds to a recepter 
on the target cell and enters the cell via endocytosis. It remains in the endocytic 
vesicle until perforin interact with the vesicle, then the granzyme is released to the 
cytoplasm of the target cell where it initiates the caspase cascade pathway, which 
result in DNA fragmentation and apoptosis (Lord, Rajotte, Korbutt, & Bleackley, 
2003).  The Th-1 and Th-17 cells both efficiently migrate through the BBB, but the 
Th-1 cells are less efficient in this migration because they do not secrete granzyme B 
or other cytolytic enzymes (Kebir et al., 2007).  
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In EAE models, it is shown that the cytokine IL-17 induces increased expression of a 
matrix metalloproteinases (MMPs) called MMP-3. MMPs are proteolytic enzymes 
that degrade the extracellular matrix and basement membranes in the BBB. MMPs 
have a role in demyelinisation, cytokine activation and axonal damage. The level of 
these proteolytic enzymes are elevated in MS patients (Waubant et al., 1999). IL-17 
also recruits neutrophils. In the granules of these neutrophils there are two kinds of 
MMPs, which are stored in their inactive forms, MMP-8 and MMP-9. These MMPs 
are released and activated by MMP-3, which results in the breakdown of the BBB and 
additional recruitment of neutrophils (Stromnes, Cerretti, Liggitt, Harris, & 
Goverman, 2008).  The Th-1 and Th-17 ratio is a determining factor for where in the 
CNS the myelin specific attack occurs. Independent of the ratio the T-cells infiltrates 
the meninges and the spinal cord, whereas if the Th-17 cells are more abundant than 
the Th-1 cells the brain is infiltrated. A higher number of Th-17 is thus needed for 
migration through the BBB (Stromnes et al., 2008).  IL-17 also induces endothelial 
cells to produce chemokines (Freiesleben et al., 2010). This local chemokine 
production contributes to the T-cell migration to the BBB and blood-CFS barrier.     
 
When the T-cells have crossed the BBB and thereby gained access to the CNS, they 
recognize local myelin antigens presented by MHC class II on APCs. When the T-
cells have interacted with the auto-antigen presented by the APCs they are reactivated 
and start attacking CNS structures with local myelin antigens. The T-cells are said to 
be reactivated because they are activated once in the peripheral blood and then again 
in the CNS KILDE. An example of an auto-antigen in MS is myelin oligodendrocyte 
glycoprotein (MOG), which is expressed extracellular on the myelin sheaths (von 
Büdingen et al., 2001). A primary immune response against defined myelin epitopes 
on myelin proteins, for example MOG, are suggested to induce T-cells to target other 
auto-antigens, for example neural cytoskeletons antigens, this lead to the 
establishment of new auto-reactive T-cells. This redirected autoimmune response will 
make a cumulative response, and the result is that multiple auto-antigens are target 
(Hohlfeld, 2009). This is called epitope spreading, and also happens when the CNS 
tissue changes and additional immunological antigens are released. Epitope spreading 
explains why antigen directed approaches in MS treating in most cases fails (Hartung 
et al., 2014). 
The reactivation of the CD4+ T-cells leads to cytokine and chemokine release, which 
mediates the disruption of the BBB and stimulate the recruitment of additional 
immune cells to CNS (Hartung et al., 2014).   
Both CD4+ and CD8+ T-cells are activated in MS and CD8+ T-cells outnumbers 
CD4+ T-cells in the immune infiltration of the CNS (Babbe et al., 2000), and CD8+ 
T-cells are also suggested to increase the permeability of the BBB (Johnson, Suidan, 
McDole, & Pirko, 2007). CD8+ T-cells directly attack and damage the myelin sheaths 
(Medana, Martinic, Wekerle, & Neumann, 2001).  
The Th-2 cells provide a protecting effect, but the development of this is inhibited in 
MS by IFN-γ released by the CD4+ T-cells. The cytokine IFN-γ acts by activating 
macrophages (Stromnes et al., 2008).  
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The T-cells also activate macrophages that secrete the pro-inflammatory cytokine 
TNF-α. The release of TNF-α is induced by IFN-γ, in this way the development of 
Th- 2 cells is inhibited (Janeway et al., 2001).  
The amount of T-regs in MS patients is equal to healthy controls, but it is suggested 
that the T-regs of MS patients lack the ability to suppress the activation of myelin 
specific T-cells in the peripheral blood (Viglietta, Baecher-Allan, Weiner, & Hafler, 
2004). 
 
The inflammatory plaques in the white matter of CNS contain B-cells, T-cells, 
macrophages, and microglia. The T-cells initiate the immune response, whereas the 
B-cells contribute to mediate the subsequent immune response (Hartung et al., 2014).  
The B-cells are recruited to the CNS when the T-cells release cytokines. The activated 
B-cells are efficient regulators of the T-cells by their secretion of cytokines. The 
activated B-cells also function as APCs, presenting myelin antigens. The cytokines 
released from B-cells result in the migration of DCs and active macrophages. This 
release of cytokines also activates additional B-cells and plasma cells, which release 
antibodies. The B-cells release antibodies that target the myelin antigens. These 
antibodies enhance the immune response and leads to additional demyelisation. The 
antibodies can also bind to macrophages and induce antibody-dependent cytotoxity. 
The B-cells secrete the cytokine IL-12 that activates NKs and induces the 
differentiation of T-cells to Th-1 cells. This regulative effect on CD4+ T-cells 
provided by the B-cells is important for the immune response. The B-cells also 
release the cytokine TNF-β which results in elimination of the antibody target, myelin 
sheaths, and an activation of adhesion molecule expression on the endothelial cells 
(Janeway et al., 2001). 
The proliferation, maturation and differentiation from B-cells to plasma cells can be 
controlled within the CNS. Under normal circumstances this control takes place in the 
lymphoid tissue. Structures like those found in the lymphoid tissues responsible for B-
cell control are also found within the meninges of MS patients. Here they provide a 
local control, which contributes to the specific pathogenic process of the B-cell 
(Magliozzi et al. 2007). The activated memory B-cells are suggested to migrate to the 
BBB because of an overexpression of chemokines, CCL12 and CXCL13, in the 
epithelium and in CNS plaques (Krumbholz et al., 2006). 
Astrocytes in MS plaques are shown to overexpress a B-cell activation factor, which 
promotes the proliferation and differentiation of the B-cells in the CNS (Krumbholz et 
al., 2006).  
Plasma cells are active in MS, this is confirmed by the presence of IgG deposits found 
in more than 50% of demyelisation lesions in MS (Lucchinetti et al., 2000). 
B-cells may also promote neuronal protection by secreting factors that can support 
neuroaxonal growth, survival, and plasticity. This could be brain-derived neurotrophic 
factor, which is an essential regulator of the survival and development of neurons 
subsequent damage (Hohlfeld, Kerschensteiner, & Meinl, 2007). This is important to 
have in mind when a B-cell targeted treatment is considered (Hartung et al., 2014). 
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Additional to this, B-cells secrete IL-10 that can limit the response of auto-reactive 
CD4+ T-cells, because IL-10 acts on macrophages where it suppresses its functions 
and thereby inhibiting the activation of Th-1 (Janeway et al., 2001). DC’s and T-regs 
also secrete the cytokine IL-10. IL-10 inhibits the production of IL-12 in macrophages 
and DC’s. The role of IL-12 is pro-inflammatory because it promotes Th-1 
differentiation and secretion of IFN-γ. IFN-γ upregulates MHC class I and II in many 
cell types, promotes Th-1 differentiation and activates macrophages. Due to the 
secretion of IL-10 T-regs and B-cells have an anti-inflammatory and tolegenic effect. 
Th-1 cells secrete IFN-γ an in this way provide a pro-inflammatory effect (Freiesleben, 
2010).  
 
Furthermore a complete loss of oligodendrocytes is observed in MS. This means that 
the formation of new myelin sheaths, the maintenance, and repairing of damaged 
myelin sheaths cannot occur (Wu & Alvarez, 2011).  
In MS patients the axons are damaged, as shown in Figure 17, because the 
demyelization leads to distortions in the ion channel homeostasis, mitochondrial 
energy failure, and blocking of nerve conduction. This triggers the neurons to undergo 
apoptosis. When the neurons are destroyed the most serious symptoms are seen 
(Hohlfeld, 2009).  
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Genetic susceptibility for Multiple Sclerosis  
Inheritance pattern in families predisposed for MS is referred to as genetic factors. An 
interaction between the genetic and environmental factors can also have an influence, 
which will give the affected person a higher risk of developing the autoimmune 
disease (Willer et al., 2007).  
MS is more often seen in women compared to men. An explanation to this could be 
that female hormones are capable of interacting with the immune system. 
Furthermore, the majority of men diagnosed with MS are over 50 years old, with a 
more progressive form compared to women, although the average age of an MS 
patient is around 45 when diagnosed (Melissa, 2006). This average is based on the 
delay between the first symptoms and the final diagnose; where the first symptoms 
appear around the twenties and early thirties, which is shown in Figure 19.   
 
 
Figure 19 shows the incidence, prevalence, and mortality of MS. The x-axis shows the decade of life and the 
y-axis shows the distribution of patients with MS (in percent). The highest rate of new diagnosis happens 
between the age of 20 to 30, which is seen as the continuous line. The long dotted line shows the number of 
people diagnosed with MS. The short dotted line shows the age of MS related deaths (Melissa, 2006).  
People related to patients diagnosed with MS, have a higher risk of develop the 
disease. Observational studies with twins, where one is diagnosed with MS, show that 
in the case of dizygotic twins the unaffected twin has a 1-5% risk of developing MS. 
If they are monozygotic the unaffected twin has a risk of 20-30% (Melissa, 2006; 
Pierrot-Deseilligny & Souberbielle, 2013). Children with a diagnosed parent have a 
0.025% risk of developing MS, in the general population the risk is 0.001% (Melissa, 
2006). To determine the contribution of heredity to MS, linkage analysis is used. 
Linkage analysis uses the fact that genes positioned close in a chromosome are more 
commonly inherited together, than genes positioned far apart. When there is more 
chromosomal distance between the genes, recombination occurs more frequently. 
Whereas genes positioned close together are more often inherited and exchanged 
together (Melissa, 2006). 
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The only confirmed genes associated with MS susceptibility are the HLA genes. Of 
these, 40% are involved in the immune system and their proteins are able to produce 
an immune response by activating T cells to attack and destroy auto-antigens in 
autoimmune diseases (Melissa, 2006). Research shows that HLA class I genes have a 
strong linkage disequilibrium (LD) with HLA class II genes (Link et al., 2012).  
LD is a deviation in frequencies of different haplotypes in a population from the 
frequencies expected if the alleles at the loci defining the haplotype are associated at 
random (Griffiths, Wessler, Carroll, & Doebley, 2012). It is suggested that there is a 
higher risk of developing MS if the combination involves the HLA-DRB1*15 allele 
(Link et al., 2012). Combinations containing the alleles HLA-A*02, HLA-B*12, 
HLA-DRB*01, and DRB*07 are not associated with MS. The allele HLA-A*0201 is 
suggested to have a protective role against MS (Link et al., 2012).  
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The influence of vitamin D in Multiple Sclerosis 
Vitamin D3 is proved to have an immunomodulatory and anti-inflammatory effect in 
MS (Christakos et al., 2010). The VDRs mentioned earlier are abundant in the 
immunity cells and in all types of CNS cells. These cells express the CYP27B1 gene 
encoding the enzyme, 1α-hydroxylase and are therefore able to form calcitriol from 
the circulating 25-OH-D. Calcitriol in the CNS appears to have an influence on 
neuronal functioning, neuro-protection, and myelination. It also functions in the 
immune response against the CNS through its effects in immune cells and is therefore 
important in relation to MS. 
Calcitriol has an anti-inflammatory effect due to its influence on macrophages, 
different types of cytokines, T-regs, invariant natural killer T-cells, and CD4+ T-cells, 
such as Th-1, Th-17, and Th-2 (Pierrot-Deseilligny & Souberbielle, 2013).  
 
 
 
Figure 20 shows the influence of vitamin D on the ration of CD4+ T-cells. Figure 20a shows how the lack of 
vitamin D increases the amount of Th-1 cells compared to T-regs and Th-2 cells. This is suggested to lead to 
autoimmunty. 20b shows how vitamin D results in an equal ratio of CD4+ T-cells, which results in normal 
T-cell function (Cantorna & Mahon, 2004).  
Vitamin D3 positively influences T-regs activity and restores a better ratio between 
Th-2 and Th-1 cells, which results in a reduction of inflammation, seen in  
Figure 20, above. When there is a vitamin D3 deficiency there is a hyperactivation of 
CD4+ T-cells, which results in an increased proliferation of Th-1. This leads to an 
immune response and when the CD4+ T-cells are activated by auto-antigens the result 
is an auto immune response (Pierrot-Deseilligny & Souberbielle, 2013). Interferon-β 
(IFN-β) has the same effect as vitamin D3 and is used in treatment of MS, because it 
blocks the expression of MHC molecules that present auto-antigens (VanPutte et al., 
2013). 
Vitamin D3 causes a reduced differentiation of monocytes to DCs and differentiation 
and proliferation of DCs, thus a decreasing T-cell stimulation.  It also helps 
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controlling T-cell activation, inhibits T-cell proliferation, and it reduces the 
production of IL-2, which is a growth factor for T-cells. Vitamin D3 suppresses the 
proliferation of Th-17 and B-cells and the secretion of pro-inflammatory cytokines. It 
also promotes Th-2 phenotype, T-reg activity and anti-inflammatory cytokines, as 
seen in  
Figure 20. Such actions of vitamin D3 through calcitriol suggests that an insufficiency 
of the vitamin plays a role in MS (Pierrot-Deseilligny & Souberbielle, 2013).  
In patients with MS it has been shown that calcitriol inhibits T-cell proliferation and 
the development of the pro-inflammatory and anti-inflammatory IL-6 and IL-17 
producing cells. Calcitriol also enhances the anti-inflammatory interleukin IL-10 
production, the number of T-regs, and stimulates CD 46. The role of T-regs is among 
others to maintain a tolerance towards auto-antigens. These mechanisms all contribute 
to an anti-inflammatory action. Vitamin D3 insufficiency thus leads to inflammation, 
which can result in degradation of the myelin sheaths (Pierrot-Deseilligny & 
Souberbielle, 2013).  
Due to the accessibility of sunlight, vitamin D3 insufficiency is widespread in 
individuals living in temperate and Nordic countries, compared to individuals living 
near the equator, there is a higher frequency of MS (Schwalfenberg, 2012). This 
knowledge has been used to treat MS, where patients are given a vitamin D3 
supplement of 28 to 280,000 IU per week, 1 IU equals 25 nanograms of vitamin D. 
This treatment has led to a decreased development of MS and reduced active 
inflammation (Schwalfenberg, 2012).  
Some studies suggest that VDREs could be involved in MS, because they exist in the 
promoter region in HLA-DRB1 alleles, which is one of the alleles that have the 
strongest association with MS (Pierrot-Deseilligny & Souberbielle, 2013).  
Other studies suggest that there are two genes involved in Vitamin D metabolism 
CYP27B1, which encode 1𝛼 -hydroxylase and CYP24A1, controlling calcitriol 
catabolism, that contributes to genetic susceptibility of MS (Pierrot-Deseilligny & 
Souberbielle, 2013).  
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Type 1 Diabetes  
T1D is an organ specific autoimmune disease in which a selective destruction of the 
β-cells in the pancreatic islets, also called islets of Langerhans, occurs. The pancreas 
and the pancreatic islets are shown in Figure 21. T1D can also be classified as a 
systemic autoimmune disease when the auto-antigen is insulin (Janeway et al., 2001). 
The pancreatic β-cells are endocrine cells, which secrete the hormone insulin. When 
the immune system targets and destroys the β-cells, the result is a declined or 
completely absent ability to produce insulin. The more progressed the disease is, the 
more β-cells are destroyed. In the end, the autoimmune reaction against the β-cells 
will result in a complete destruction of the β-cells, and no secretion of insulin. When 
there is a lack of insulin, or total insulin deficiency, the cells cannot take up blood-
glucose and therefore not utilize blood-glucose in their metabolism. The cells’ 
metabolism is then completely dependent on lipids, which are stored in the liver and 
adipose tissue. The lipid catabolism produces ketone bodies. They are poisonous for 
the body in large amounts, and the accumulation of these, result in a characteristic 
smell. When there is no insulin, the glucose cannot be metabolised and thereby 
removed from the blood, this result in hyperglycaemia. Hyperglycaemia is a condition 
where high amounts of glucose circulate in the blood and is secreted in the urine 
(VanPutte et al., 2013). 
 
Figure 21 shows the pancreas that contains the pancreatic islets, also called the islets of Langerhans. The 
pancreas lies between the stomach and the duodenum. The β-cells make up 60-80% of the islets and are 
thereby the dominant cells in the islets, and are shown as the almost white cells.  The α-cells are shown in 
dark purple and the δ-cells are shown in green (VanPutte et al., 2013). 
A T1D patient is treated with insulin injections several times a day. As a result of the 
injections the patient’s blood-glucose level remains relative stable at a reasonably 
point between hyperglycaemia and hypoglycaemia. Hypoglycaemia is a condition 
where low amounts of glucose circulate in the blood (VanPutte et al., 2013). 
T1D is different from other autoimmune diseases because the immune response, in 
the end, can destroy the auto-antigen source, the β-cells, almost completely and 
eliminate them from the body (Janeway et al., 2001).  
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The destruction of β-cells is highly selective. The α-cells, which produce and secrete 
glucagon, and δ-cells, which produce and secrete somatostatin, are left unharmed by 
the immune system.  
 
 
 
Figure 22 shows how only the β-cells are degraded by the CD8+ T-cells while the α- and δ-cells remain 
unaffected by the autoimmune response. This is due to the fact that the CD8+ T-cell recognize an auto-
antigen, which is only found in the β-cell. This auto-antigen is therefore a unique protein produced by or 
found in the β-cell (Janeway et al., 2001). 
The autoimmune response in T1D is mediated by different subsets of T-cells, which 
specifically targets an auto-antigen presented by MHC molecules on the β-cells. The 
auto-antigen can be a protein, produced by or found in the β-cell. In every case of 
T1D the auto-antigen is a unique product of the β-cell. That the auto-antigen is a 
product unique for the β-cells is confirmed by the high selectivity for β-cells by the 
CD8+ T-cell and other immune cells, this is illustrated  
Figure 22, above. The unique protein is presented on APCs by MHC class I 
molecules, and CD8+ T-cells recognize this presented antigen and react by eliminate 
the β-cell. MHC class II molecules that are recognized by CD4+ T-cells also present 
the auto-antigen. Insulin is a unique β-cell product and often found as an auto-antigen 
in T1D. When insulin is an auto-antigen it explains the highly specific attack on the 
β-cells.  
There are four major antigens involved in T1D, insulin was the first identified. The 
remaining three are glutamic acid decarboxylase 65-kDa isoform (GAD65), an 
intracellular phosphatase called insulin auto-antigen 2 (Nokoff & Rewers, 2013) and 
zinc transporter 8 (Wenzlau et al., 2007). No matter which of these antigens are 
involved the result are the same: specific CD4+ and CD8+ T-cells selectively destroy 
the β-cells of the pancreatic islets (Freiesleben et al., 2010).  APCs are able to present 
intracellular proteins to the interacting T-cell due to their phagocytizing abilities. 
Endogenous matter, such as dead or destroyed β-cells, are phagocytized into its 
components, and both intra- and extracellular proteins are free and able to be 
transported to the MHC molecule on the surface of the APC (Goldsby et al., 2003). 
 
 
 38 
CD4+ and CD8+ T-cells mediate the adaptive autoimmune response against the β-
cells, and the pancreatic islets of T1D patients are therefore infiltrated by both CD4+ 
and CD-8+ T-cells. Studies in animal models have shown that both CD4+ and CD8+ 
T-cells are needed in T1D development, and that T1D fails to develop if no 
macrophages are present. The macrophages are essential because they secrete 
cytokines such as IL-1β and TNF-α (Bending, Zaccone, & Cooke, 2012). These 
cytokines creates an inflammatory state and attracts additional immune cells. The 
CD4+ T-cells selectively activates B-cells that bind to the antigen epitopes, which is 
found on the antigen presented by the MHC class II molecule. The activated B-cells 
produce antibodies specific for the epitopes. These antibodies bind to the epitopes and 
then aids in the elimination of the β-cell. By the activation of B-cells, T1D becomes a 
result of both a T-cell and antibody mediated autoimmune response. Figure 23 
illustrates the immune response that is activated in T1D. The response is also called a 
T-cell dependent reaction (Janeway et al., 2001). 
 
 
Figure 23 shows a case of CD4+ and CD8+ T-cells immune response. In 23A the antigen is first taken up by 
an antigen presenting cell. The antigen is then presented to the CD4+ T-cells. The CD4+ T-cells then release 
cytokines and chemokines. These affect the vascular endothelial cells and facilitate the recruitment of 
additional T-cells, macrophages, and other inflammatory cells. The final result is an inflammation in the 
pancreatic cells. Figure 23B shows how the cytotoxic CD8+ T-cells destroy the target cell by inducing 
necrotic cell death (Kumar, Abbas, Fausto, & Aster, 2009). These activated effector T-cells, which react 
specifically against the auto-antigen presenting MHC class I molecule on the β-cell. This leads to a local 
inflammatory response, by the activation of macrophages and the release of cytokines and chemokines. The 
effector T-cells can also directly damage the pancreatic islets; this is the cytotoxic effect of CD8+ T-cells 
(Janeway et al., 2001).  
This immune cell infiltration of the pancreatic islets is referred to as insulitis. Insulitis 
is defined by the presence of more than five immune cells in one islet, because the 
maximum number found in healthy pancreatic islets is five immune cells (Willcox, 
Richardson, Bone, Foulis, & Morgan, 2009). Insulitis progresses in various stages. In 
the first stage of insulitis, immune cells are observed in the periphery of islets and no 
Antigen 
MHC I 
MHC II 
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change in the number of β-cells is observed. In the second stage, the number of β-
cells starts to decline and the immune cells become more scattered in and around the 
islets. In the third stage, immune cells are still present and islets with a complete 
deficiency of β-cells are present. These islets represent the end stage of the 
destructive auto immune response.  
During the first stage of insulitis the most abundant infiltrating immune cells found in 
inflamed islets are CD8+ T-cells. The number of CD8+ T-cells peaks, as the number 
of β-cells starts to decline. The CD8+ T-cells kill the β-cells by secreting perforin and 
granzymes, which leads to necrotic cell death. As a result of the CD8+ T-cell 
mediated decline in number of β-cells, the number of CD8+ T-cells starts to decline, 
as the last β-cells are destroyed (Willcox et al., 2009).   
Figure 24 shows how the different immune cells decrease in the progression of T1D.  
 
Figure 24 shows the number of immune cells as T1D progresses. The x-axis shows the percentage of the area 
of pancreatic islets that are positive for insulin, hence positive for β-cells. The percentage declines along the 
x-axis, this corresponds to the progression of the disease and the decline in numbers of β-cells.  The y-axis 
shows the number of immune cells observed in the islets. The plot shows the number of infiltrating immune 
cells in pancreatic islets at different β-cell percentages. n indicates the number of pancreatic islets found and 
analyzed in the T1D patients. The figure shows how the CD8+ T-cells are the most abundant immune cells 
and the number peaks as the last 10% of the β-cells are destroyed. At this point, all four kinds of the 
immune cells peak. Modified (Willcox et al., 2009). 
Macrophages are, as shown in Figure 24, present at a relatively constant level 
throughout all stages of insulitis. Macrophages contribute to the destruction of β-cells 
by secreting pro-inflammatory cytokines, such as TNF-α and IL-1β, which can 
induce expression of Fas on the β-cell and thus induce Fas receptor binding of the Fas 
ligand on activated CD8+ T-cells (Uno et al., 2007). This ligand and receptor 
interaction induces apoptosis of the cell. The Fas pathway provide selective 
destruction of β-cells by apoptosis (Moriwaki et al., 1999). In addition to these two 
cytokines, it is suggested that IFN-γ is an important cytokine in T1D. IFN-γ is 
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secreted by CD4+ effector T-cells. It contributes to the inflammation of the pancreatic 
islets and upregulation of MHC class II expression in the pancreatic cells.  
The pancreatic islets cells do not express MHC class II under normal circumstances. 
The pro-inflammatory cytokines, IL-1β, TNF-α, IFN-γ, play the most central role in 
β-cell failure and in the development of an inflammatory state in the pancreatic islets. 
They influence the β-cells with a synergic effect, meaning that the three cytokines 
combined result in a higher effect than they would, if they were isolated from each 
other and not present simultaneously (Bending et al., 2012). It should be mentioned, 
that other cytokines and chemokines are involved in T1D. A prolonged exposure to 
cytokines leads to a decline in β-cell function and can eventually lead to necrosis or 
apoptosis of the β-cells (Nokoff & Rewers, 2013; Thomas & Kay, 2011).The 
inflammatory state in the pancreatic tissue contributes to necrotic cell death, and the 
inflammatory state co-stimulates the antigen presenting cells.  
When the number of β-cells starts to decline there is a large increase of specific B-
cells (Willcox et al., 2009). Mice models of T1D has suggested that these B-cells are 
necessary for the survival of CD8+ T-cells and do not produce antibodies (Brodie, 
Wallberg, Santamaria, Wong, & Green, 2008). 
Like macrophages, the CD4+ T-cells are also present at a relatively constant level 
throughout all insultitis stages. There is still some uncertainty in defining these CD4+ 
T-cells subgroups. It has been suggested that there is a balance between Th-1 and Th-
2 that may determine which cells dies and which is protected from the autoimmune 
response (Sia, 2005). Th-17 is also suggested to have a pro-inflammatory role in T1D, 
but it cannot cause T1D on its own (Cooke, 2006). 
It has also been suggested that T-regs have a regulatory function in the inflammatory 
process (Putnam, Vendrame, Dotta, & Gottlieb, 2005). The T-regs are not found in 
the pancreatic islets, and therefore do not act directly on these. The T-regs are 
suggested to have a function in the pancreatic lymph nodes, where they may be 
dysfunctional in the exclusion of auto-reacting T-cells (Willcox et al., 2009).   
B-cells are present in every stage of insulitis but the number increases as the number 
of β-cells decline, and finally DCs are also infiltrating the pancreatic islets (Uno et al., 
2007). T-regs, plasma cells and NK cells are rarely found, which indicates that they 
do not directly mediate β-cell destruction. All these immune cells target the β-cells 
and mediate the selective destruction of β-cells, resulting in T1D (Willcox et al., 
2009).  
 
The inflammatory state, created in the pancreatic islets, exposes the β-cells for 
multiple stress mediators, hyperglycemia and reactive oxygen species (ROS). The 
macrophages contribute to this stress by releasing different ROS. In a stressed 
environment ER stress may develop, this ER stress courses dysfunction of the β-cells 
and contributes to the onset of T1D (Zhong, Rao, Xu, Yang, & Wang, 2012).  
ROS are molecules such as superoxide, O2-, and hydrogenperoxid, H2O22-, which 
contains oxygen and are chemical active. The molecules are created as biproducts 
during the cell metabolisme. When ROS are found in high concentrations they can 
 41 
create oxidative stress, which leads to an inflammatory state. Through their role in 
redox-dependent signalling pathways ROS induce the synthesis of pro-inflammatory 
cytokines, which promotes the maturing of the adaptive immune cells. The ROS and 
pro-inflammatory cytokines provide a signal for a complete activation of effector T-
cells. Without the ROS and the pro-inflammatory cytokines only the promotion of 
naive T-cells would be induced (Padgett, Broniowska, Hansen, Corbett, & Tse, 2013).  
When NK cells interact with MHC I molecules they receive an inhibitor signal which 
minimises the cytotoxic effect of NK cells. The hyperexpression of MHC class I 
observed in T1D thus argue against the destruction process of NK cells (Vivier, 
Nunès, & Vély, 2004). The mentioned presence of only few NK cells in T1D patients 
may therefore be explained by the hyperexpression of MHC class I molecules.  
 
It has been suggested that the onset of an organ specific autoimmune disease, such as 
T1D, is initiated by MHC class II expression on target cells (Bottazzo, Pujol-Borrell, 
Hanafusa, & Feldmann, 1983). When there are no MHC class II molecules on the 
cells, they cannot present auto-antigen for the CD4+ T-cells. When the cells start to 
express MHC class II molecules, the auto-reactive CD4+ T-cell immune response is 
initiated. In T1D patients, every endocrine cell in the pancreas shows a 
hyperexpression of MHC class I molecules (Richardson et al., 2011). A 
hyperexpression of MHC class II molecules on the β-cells is only observed with a 
preceding hyperexpression of MHC class I molecules. The hyperexpression of MHC 
class II is not observed in every inflamed islet, and likewise for the hyperexpression 
of MHC class I (Richardson et al., 2011). A study shows that only approximately 50% 
of the cells that hyperexpressed MHC class I and II were infiltrated by immune cells 
(Pujol-Borrell et al., 1986). When the number of β-cells declines, this 
hyperexpression of MHC class I in the additional endocrine cells declines as well. 
The additional endocrine cells of the pancreatic islets therefore only show a 
hyperexpression when they are associated with β-cells in inflamed islets. The β-cells 
can produce and release the cytokine IFN-α, or another factor which induces this 
hyperexpression of MHC class I molecules in the additional endocrine cells 
(Richardson et al., 2011).  
The release of IFN-α by the β-cells is observed in association with a viral infection, 
such as an enterovirus, of the β-cells. The release of IFN-α causes a release of 
different chemokines and additional cytokines and induces hyperexpression of MHC 
class I. This may be the connection when a virus infection is claimed to be the cause 
of an autoimmune disease (Richardson et al., 2011).  
 
Another explanation for why the additional endocrine cells in the pancreatic islets do 
not show a hyperexpression of MHC class I when the β-cells has been destroyed, is 
due to the absence of an immune infiltration in the pancreatic islets. 
When there is no immune infiltration there are no cytokines and therefore the 
endocrine cells receive no signals to express additional MHC class I molecules.  
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The hyperexpression of MHC class I molecules are present before insulitis occur. 
Insulitis is never observed without this hyperexpression of MHC class I, whereas 
hyperexpression is observed without subsequent insulitis. The first step in this 
hyperexpression resulting in insulitis is therefore the MHC I hyperexpression, this can 
be followed either by insulitis or by hyperexpression of MHC II and then insulitis 
(Foulis, Farquharson, & Hardman, 1987).  
The factors suggested to induce the hyperexpression of MHC class I in humans are 
IFN-β and IFN-α. The cytokine IFN-α was in a study found in 33 out of 34 T1D 
patients (Foulis, Farquharson, & Meager, 1987). The cytokine induce the 
hyperexpression of MHC class I and the release of various chemokines, such as 
CXCL10, which is involved in the recruitment of activated T-cells (Hultcrantz et al., 
2007). In mouse models the CXCL10, released from macrophages, fibroblasts and 
endothelia cells, leads to a spontaneous infiltration of immune cells, which express 
the CXCL10 cognate receptor, CXCR3. This release results in an increased T1D 
progression (Rhode et al., 2005).  
In T1D patients an increased amount of adhesion molecules, ICAM-1, present on 
endothelial cells and other cells around the islets are observed. The adhesion 
molecules increase makes the endothelial and other the cells bind effector T-cells 
more efficient, this means that more T-cells are found in the infection site, in this case 
the β-cells, and hence an enhanced immune response against the β-cells present in the 
islets (Richardson et al., 2011). This increased level and the hyperexpression of MHC 
molecules are likely to be involved in the selective recruitment and activation of auto-
reactive immune cells (Willcox et al., 2009).  
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Genetic susceptibility for Type 1 Diabetes 
T1D is a result of a complex interaction between environmental factors and gene 
products arising from several loci. If one monozygotic twin has T1D, the other twin 
develops T1D in approximately 50% of the cases (Rakyan et al., 2011). HLA alleles 
are thought to account for 50% of the genetic risk in developing T1D (Stankov et al., 
2013). The HLA class II genes, primarily the HLA-DRB1, the HLA-DQA1 and the 
HLA-DQB1, have a major role in the genetic susceptibility for T1D.  (Grant, 
Hakonarson, & Schwartz, 2010).  Roughly 90% of children with T1D have the 
haplotypes DR4-DQ8 and DR3-DQ2 (Gillespie, 2006). The frequency of DR4-DQ8 
is 0.4% in individuals that represent a normal healthy population (Klitz et al., 2003). 
It has been shown that approximately 98% of all T1D patients, with parents who had 
T1D, have the serotypes HLA-DR4, where the allele DQB1*0302 in most T1D cases 
is found, or HLA-DR3, where the allele DQB1*0201 is found. The frequency of the 
serotype HLA-DR3 and HLA-DR4 in a normal healthy population are respectively 
13.1% and 16.9% (Klitz et al., 2003). Heterozygotes carrying these two alleles have 
the highest risk of developing T1D (Pugliese et al., 1995). There are 30-50% T1D 
patients who are heterozygote with DR3-DQ2 or DR4-DQ8 (Wolf, Spencer, & 
Cudworth, 1983). The allele frequency of DR3-DQ2 in a non T1D affected 
population is 13.2% and 4.6% for DR4-DQ8 (Klitz et al., 2003).   
 
The serotype HLA-DR2 is rarely found in T1D patients and this serotype therefore 
may provide a protection against the development of T1D (Janeway et al., 2001).  
The haplotype provided by the alleles DQB1*0602 is strongly associated with 
protection against T1D. Only 0.55% patients had the allele DQB1*0602, this allele is 
found in 20-25% of the general population (Pugliese et al., 1995).  
The HLA class 1 genes also contribute to the genetic risk. Particularly one of these 
class I genes, HLA-B39, are in strong association with increased risk of T1D. This 
allele was found to have a relative risk of 3.55 (Nejentsev et al., 2007). This means 
that individuals with the allele HLA-B39 have 3.55 times the risk of developing T1D, 
as individuals that do not have the allele.  
 
Increased risk of T1D is not only associated with the HLA genes. Many non-HLA 
genes contribute in a minor degree to an increased risk of T1D, among those are 
genes for insulin, CTLA4, PTPN22, IF-IH1, and interleukin 2 receptor, IL2RA 
(Morahan, 2012; Nepom & Buckner, 2012). As an example, of why these particular 
genes are involved in T1D, the gene PTPN22 modulates the IFN-γ induced β-cell 
apoptosis. This means that this gene influences the effect that IFN-γ has in causing 
apoptosis of β-cells (Bending et al., 2012). 
The remaining genetic susceptibility is not accounted for, because the genetic analysis 
available today cannot detect gene-gene and gene-environment interactions (Pociot et 
al., 2010). A gene-environment interaction depends on environmental factors as well 
as genetic factors for developing T1D. An environmental factor could be an 
inconvenient diet, a virus infection or vitamin D deficiency (Knip et al., 2005).  
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The influence of vitamin D on Type 1 Diabetes 
Vitamin D has important effects in bone tissue and calcium homeostasis. In addition, 
it is linked to a range of health problems and diseases such as T1D (Wolden-Kirk et 
al., 2011). T1D is an autoimmune disease that is inhibited by calcitriol 
(Schwalfenberg, 2012). 
A study show that people with a newly diagnosis of T1D have low vitamin D3 levels 
in their blood. In general T1D patients are more sensitive to ultraviolet light, and have 
less pigmentation in their skin. The lack of sun exposure could be a possible 
explanation of why lower vitamin D3 levels are observed in people with T1D. Little is 
known about vitamin D3 status in patients previous to diagnosis, which is defined as 
the presence of multiple islet auto-antibodies (Raab et al., 2014).  
Vitamin D3 has a positive influence on the progression of T1D. Only one study has 
investigated the link between islets autoimmunity and the progression of diabetes, 
influenced by vitamin D3 intake and 25-OH-D levels in childhood. The investigators 
did not find any association between vitamin D3 and progression in diabetic 
symptoms (Raab et al., 2014). The result did show, that out of the participants in 
which there was a presence of islet auto-antibodies, there were a large amount with 
single islet auto-antibodies and therefore a low risk of progression to diabetes is 
associated (Raab et al., 2014). 
Research has shown that the human genome has 2276 VDREs and at least 229 genes 
are associated with the disease T1D (Schwalfenberg, 2012). Numerous of the sites are 
concentrated around genes that are linked to autoimmune conditions. Furthermore, 
studies have shown that T1D is a vitamin D3 sensitive disease that is directly related 
to the degree of latitude in which people live. It is also known that young adults with 
a BMI higher than 25 as well as lower plasma levels of 25-OH-D are at greater risk of 
developing T1D. It has been shown that lack of vitamin D3 in early life is linked to the 
development of T1D. Therefore, the risk of developing T1D is significantly reduced 
by supplementation of vitamin D3 intake during early childhood.  
By increasing the dosage of vitamin D3 in infants, over the past 30 years, the 
development of T1D has been reduced by 78% (Schwalfenberg, 2012). 
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Analysis and discussion 
For this part of the project, the genes involved in MS and T1D will be discussed and 
compared, to investigate if there is a possibility of developing one of the diseases if 
you are already affected with the other. The beneficial role of calcitriol will also be 
discussed in terms of whether it can prevent the development of the two diseases or 
can be used to resolve them. The general role of calcitriol in immune function and in 
the genetics involved in these autoimmune diseases will also be discussed. 
Furthermore the involvement of Th-1, Th-2, and Th-17 cells and their ratio will be 
discussed. The immune response in the two diseases will also be discussed and 
compared.  
Genetic susceptibility for Multiple Sclerosis and Type 1 Diabetes   
MS and T1D show genetic similarities because both autoimmune diseases are 
associated with specific gene variants located in the HLA region on the short arm of 
chromosome 6p21. This region encodes three classes of HLA genes, and both 
diseases have the strongest association with the class II genes. MS and T1D have 
specific MHC molecules encoded by the HLA class II in common, which are 
illustrated in Figure 9 (Grant et al., 2010; Link et al., 2012; Yeo et al., 2007). The 
genes that are said to cause susceptibility for MS and T1D are seen in Table 2. The 
specific HLA gene, HLA-DRB1, encode the same MHC molecule in both diseases, 
this specific molecule could be responsible for susceptibility for both diseases. 
Therefore a similar inheritance between MS and T1D might exist, and furthermore 
having this particular allele may contribute to the risk of developing several 
autoimmune diseases, for example T1D if a person is already affected with MS.  
 
Table 2 shows the HLA genes associated with both MS and T1D respectively. These genes might be 
responsible for the development of both diseases (Goris et al., 2012; Grant et al., 2010; Pugliese et al., 1995). 
 
HLA class I and II genes in MS  HLA class I and II genes in T1D 
HLA-DRB1 (*0301,*1303,*1501) HLA-DRB1 
HLA-A (*0201) HLA-DQA1 
HLA-B (*12,*14,*18) HLA-DQB1 
HLA-C HLA-DR4 
 HLA-B 
 
Autoimmune diseases have the ability to cause the development of another 
autoimmune disease (Goris et al., 2012). This could be due to the fact that 
autoimmune diseases share several genes with other autoimmune diseases, for 
instance MS share several genes with T1D as shown in Table 2. An explanation could 
be that the genes associated with MS, tend to cluster together (Goris et al., 2012).  
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This means that individuals could inherit not just one but several associated genes. 
Given that T1D and MS share some genes within this cluster, it is likely they are 
inherited together. The clustering could in this case give rise to a negative effect on 
the genes that control another autoimmune disease. 
 
Studies shows that there are strong associations between DRB1 and DQB1, but it is 
not yet established which of them are responsible for the association, because of high 
polymorphism in the region (Lincoln et al., 2005; Yeo et al., 2007). This should mean 
that if an individual inherit both genes, the risk of developing more than one 
autoimmune diseases are much larger compared to the inheritance of only one of the 
genes. Several studies show that both MS and T1D are associated with DRB1 and 
DQB1 (Goris et al., 2012; Pugliese et al., 1995; Yeo et al., 2007).    
 
In T1D patients a hyperexpression of both MHC class I and II molecules, presenting 
auto-antigens, is observed. This supports the fact that both CD4+ and CD8+ T-cells 
are mediators of the autoimmune response. Both CD4+ and CD8+ T-cells also 
mediate the autoimmune response of MS. Both diseases are associated with specific 
genes in both HLA class I and II genes. This leads to the suggestion that these specific 
genes could encode molecules that posses an ability to present auto-antigens. If these 
genes were different, the MHC molecules might lack this ability and autoimmunity 
could be prevented.  CD4+ T-cells are mediators of several autoimmune disease 
(Janeway et al., 2001). The MHC class II molecules that activate the CD4+ T-cells are 
able to present auto-antigens, this might be due to a HLA class II gene that encodes an 
ability for the MHC molecules to bind auto-antigen. This is supported to be the 
association with HLA class II genes in several autoimmune diseases.   
 
Over the last 10 years genome wide association study (GWAS) has been performed 
and used as a method to scan an entire genome for gene variation. The GWAS is a 
genetic study in which large numbers of samples are genotyped at a genome-wide set 
of single nucleotide polymorphisms (SNPs). These are analysed and statistical 
associations between the genetic variants and the phenotype are found. GWAS has 
contributed to knowledge about inheritance pattern in humans on the basis of SNPs, 
which are the most common type of genetic variation in the population. There are 
about 3 million SNPs in the human genome, these are located both within the exons 
and within the introns (Griffiths et al., 2012). Figure 25, on the next page, shows an 
example of a GWAS based on T1D patients and how the SNPs are associated with the 
HLA-DRB1 gene at chromosome 6 (Griffiths et al., 2012). The GWASs have 
furthermore identified 140 polymorphic regions in the genome that have association 
with autoimmune diseases, including T1D (Sirota & Schaub, 2009).  
Sirota et al. states that SNPs are expressed differently in individuals, meaning that 
genetic and environmental factors can change the SNPs, which could have both a 
positive or negative influence on the development of autoimmune diseases in humans 
(Sirota & Schaub, 2009). So even though you have SNPs associated with an 
autoimmune disease, it does not necessarily develop.   
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Figure 25 shows a genome wide association study of T1D patients. The x-axis shows the 23 human 
chromosomes and the y-axis the P value for the associations with SNPs. The green dots illustrate the SNPs 
associating with the HLA-DRB1 genes, which regulate the immune response in humans. The figure also 
shows protein tyrosine phosphate gene (PTPN22), which are also associated with the susceptibility of T1D 
(Griffiths et al., 2012) 
Besides HLA genes, other genes are also confirmed to have an association to 
autoimmune diseases, including MS and T1D (Berge, Leikfoss, & Harbo, 2013; 
Rasmussen, Kelly, & Clausen, 2001; Zoledziewska et al., 2009). These associations 
are also revealed by GWAS (Griffiths et al., 2012).  Close to 60 genes associated with 
MS were identified in 2012. These genes are located within or near genes important to 
the immune system, especially T-cells (Berge et al., 2013). It could be suggested that 
these genes have mutations that could influence the development of dysfunctional T-
cells. Dysfunctions in T-cells will affect the rearrangement of the antigen-receptor 
genes and the expression of their protein product. This could also result in a 
dysfunctional selection of the lymphocytes and the T-cells can therefore be able to 
initiate damaging autoimmune reactions.  
 
SNPs in the C-type lectin-like domain family 16 A (CLEC16A) gene are among the 
genetic variants that shows suggestive association with autoimmune diseases, 
including T1D and MS (Berge et al., 2013). The CLEC16A gene is expressed in 
immune cells, which indicates that the CLEC16A product might play an important 
role in immune regulation (Berge et al., 2013). The CLEC16A gene is located at 
chromosome 16p13 in a region including several other immune regulatory genes. 
SNPs variants of CLEC16A, which is found in the same position in both MS and 
T1D, are rs12708716 and rs725613 located in intron 19 with perfect LD, r2=1 and 
rs6498169 located at intron 22 of the same gene with LD; r2=0.2. All of these are seen 
on Figure 26, on the next page (Berge et al., 2013; Zoledziewska et al., 2009).  
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Figure 26 shows the CLEC16A gene with the autoimmunity associated single nucleotide polymorphisms and 
their location. The autoimmune disease: Celiac disease (CD), Primary biliary cirrhosis (PBC), Alopecia 
areata (AA), and Rheumatoid arthritis (RA), will not be discussed in the project. Modified (Berge et al., 
2013). 
To confirm the association between MS, T1D, and the variations of the CLEC16A 
gene, a selected marker, rs725613 was used, because of the strong LD (Zoledziewska 
et al., 2009). The study was based on the Sardinian population. 
The marker was typed in 1037 independent T1D cases, 1498 MS cases, and in 1706 
controls (Zoledziewska et al., 2009).  
By comparing allelic and genotypic frequencies in all patients and controls for 
rs725613, the association analysis showed that allele A of rs725613 have a frequency 
of 47% in T1D patients and therefore overrepresented when compared with the 
control frequency of 43%. The same was observed in MS patients, where allele A had 
a frequency of 48%, these result are also seen in table 3 (Zoledziewska et al., 2009). 
This study suggested that patients with allele A have the SNP rs725613 and is 
therefore predisposed and have an increased risk for developing both diseases. If this 
is SNP is in addition to other genetic risk, such as certain HLA genes, the 
susceptibility would be enhanced.  
 
Table 3 shows results of an association analysis of variant rs725613 within CLEC16A. The table shows that 
allele A has a higher frequency in both MS and T1D, which indicates a higher risk for development. Allele 
C has approximately the same frequency in both autoimmune diseases and in the controls. This suggests 
that allele C does not carry the SNP variant and thus does not influence the development of MS or T1D 
(Zoledziewska et al., 2009). 
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The 16p13 chromosomal region where CLEC16A is placed has been investigated in 
several autoimmune diseases, including MS and T1D. In this region, two immune 
regulatory genes with interest for autoimmunity have been located close to 
CLEC16A. The two immune regulatory genes are the MHC class II transactivator 
(CIITA) gene and the suppressor of cytokine signalling 1 (SOCS1) gene (Berge et al., 
2013). These genes are seen in Figure 27. 
 
 
Figure 27 shows a schematic drawing of the chromosome 16p13 that contains the immune regulatory genes: 
CIITA, DEXI, and SOCS1. Modified (Berge et al., 2013) 
 
CIITA encodes an essential transcription factor, which regulates gene expression of 
HLA class II molecules and is required for MHC class II antigen presentation 
(Bronson et al., 2010). Genetic defects can prevent expression of functional CIITA, 
which can lead to the development of an immune defect disease characterized by 
downregulation of MHC class II molecules (Rasmussen et al., 2001). A 
downregulation of MHC class II molecules is characterized by a lack of HLA class II 
gene expression, absence of T-cell immune response to foreign antigens, and 
decreased antibody production. These defects can result in susceptibility to viral and 
bacterial infections (Elhasid & Etzioni, 1996). A study by Ercolini & Miller has 
shown that infection by a pathogen carrying elements similar in amino acid sequence 
or structure to auto-antigen, the pathogen then acts as a auto-molecular mimicry 
which can lead to autoimmunity. This results in the cross-activation of auto-reactive 
B- or T-cells by pathogen antigens. In other words if the antigen fragment presented 
to the T-cell closely resembles part of an auto-antigen, then the immune system will 
not only attack the foreign pathogen but also the similar string in an auto-antigen. 
This will create an autoimmune response (Elhasid & Etzioni, 1996). 
CIITA has been suggested as T1D and MS candidate gene because of the strong 
association to HLA-DRB1*1501 in MS and HLA-DRB1, HLA-DQA1, and HLA-
DQB1 in T1D (Berge et al., 2013).  
The only confirmed association in CIITA SNPs, is between rs4774 and HLA-
DRB1*1501. This suggests that rs4774 is associated with increased MS risk in the 
presence of DRB1*1501 (Berge et al., 2013; Bronson et al., 2010).  
Furthermore, a report shows that both T1D and MS share a common SNP in the 
promoter variant, rs3087456, which could have an influence on the transcription of 
the human CIITA gene (Rasmussen et al., 2001). However a multi-study did not 
confirm this association between rs3087456, MS, and T1D (Bronson et al., 2010). 
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SOCS1, the suppressor of cytokine signalling, is important for immune cell 
homeostasis and regulation of inflammation (Fenner et al., 2006). SOSC1 includes 
several SNP variants, were only rs1640923, rs12922733, and rs243324 are found in 
association with MS (Berge et al., 2013). It could be suggested that these SNP 
variants of the gene found in association with MS does not work properly, because of 
this cytokine signalling will be decreased and dysfunctional. Dysfunctions in cytokine 
signalling could result in a low migration of immune cells to the infection site and no 
inhibition of proliferation of B- and T-cells. 
 
The dexamethasome-induced gene (DEXI) placed between CLEC16A and CIITA, 
has been suggested to be a autoimmune regulatory gene, which have a protective 
effect against autoimmune diseases (Davison et al., 2012). The function of the protein 
encoded by the DEXI is still unknown. It is known, though, that its transcript is 
induced by glucocorticoid analogue, dexamethanose, which is an immune suppressive 
drug (Berge et al., 2013). This could suggest that DEXI inhibits or prevents activity of 
the immune system under autoimmune responses. 
Even though these neighbouring genes have several autoimmune disease associated 
SNPs, SNPs within intronic regions of CLEC16A appears to have the strongest 
association with both MS and T1D (Berge et al., 2013). Because of the selective 
expression of CLEC16A in immune cells and due to their association with MS, T1D, 
and other autoimmune diseases it is necessary to investigate the CLEC16A gene and 
the encoded molecule to understand new pathological mechanisms in the 
development of autoimmunity (Berge et al., 2013). Furthermore it is difficult to 
identify the primary genetic association in the gene region of CLEC16A, because 
many of the identified SNPs are in strong LD (Berge et al., 2013). A strong LD means 
that a specific allele at the first locus is associated with a specific allele at the second 
locus more often than expected by chance. 
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The role of Vitamin D3 in Multiple Sclerosis and Type 1 Diabetes  
The active metabolite of vitamin D3, calcitriol, may be involved in the maintenance of 
a normal functioning immune system. When bound to VDREs, calcitriol exerts a local 
effect by either suppressing or promoting gene expression. Thereby calcitriol has the 
potential to influence which gene is expressed by the immune cells and other cells, 
such as genes encoding specific cytokines.   
The fact that VDRs and VDREs are present and CYP27B1, the gene that encodes 1α-
hydroxylase, is expressed in immune cells indicates that calcitriol has a regulatory 
function on the genes expressed by these cells. VDRs are also expressed in the cells 
of CNS, including both oligodendrocytes and astrocytes. Calcitriol are thus likely to 
provide a regulatory function in myelination and BBB maintenance (Pierrot-
Deseilligny & Souberbielle, 2013). Calcitriol therefore has a possible function in MS 
and immune function in general.  
 
In monozygotic twins 20-30% develop MS if the co twin has the disease, and in T1D 
the risk is 50%. This suggests that there must be one or more environmental factors 
contributing to the development of the diseases, contributing to the genetics. Such an 
environmental factor is suggested to be vitamin D3 deficiency, which is related to 
UVB radiation from the sun. In a study by Janner et al., a level under 50 nmol/L of 
25(OH)D3, the amount needed for vitamin D3 to conduct its classical functions, is 
defined as vitamin D3 deficiency (Janner, Ballinari, Mullis, & Flück, 2010). Vitamin 
D3 sufficiency is defined as a level above 75 nmol/L of vitamin D3, which is the level 
where vitamin D3 can provide its optimal effect. This level is needed for optimal bone 
health and to benefit from other vitamin D3 related functions (Janner et al., 2010). 
Vitamin D3 insufficiency is thus defined as more than 50 nmol/L but less than 75 
nmol/L.  
The geographic pattern of the disease occurrence and frequency supports the role of 
UVB exposure. Incidences of both T1D and MS are higher in populations living 
above 35o latitude (Holick F Michael, 2004). Denmark is located within the latitude of 
55o (GPS coordinates, 2014). Above the 35th latitude there is not enough UVB to 
produce sufficient amounts of Vitamin D3 in the skin. The higher disease frequency is 
thus hypothesized to be due to the lack of UVB light, and the subsequent vitamin D3 
insufficiency (Holick F Michael, 2004). Individuals who have are genetically 
predisposed to MS, but live in areas with high amounts of UVB do not develop MS as 
frequently as individuals with the same genetic combination living in areas with a 
lower amount of UVB (Hayes, 2014).  
A EAE study made by Becklund et al. has suggested that the protection against MS 
observed in context with sun exposure is not due to calcitriol (Becklund, Severson, 
Vang, & DeLuca, 2010). Instead it is due to the UVR light itself. The study claims 
that the UVR provides the autoimmune suppressive effect, without the influence of 
vitamin D3. The study suggests that UVR suppresses EAE independently of the levels 
of vitamin D3 because the result of this study were that the levels of vitamin D3 
subsequent the UVR were too low to have a disease suppressing effect. In spite of this 
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the EAE mice showed suppressed signs of the disease. This is based on studies of 
EAE models and is not shown in humans (Becklund et al., 2010).  
Even though it turns out that UVR itself provides an autoimmune suppressive effect 
in humans, it is in a variety of studies shown that vitamin D3 is directly involved in the 
protection. UVR and vitamin D3 may play independent roles, each providing 
beneficial effects on the immune response. This may suggest that vitamin D3 obtained 
in context with UVR may provide the best protection against MS and T1D. 
 
It is shown that 76% of MS patients experienced relapses of the disease during the 
wintertime, and improvement during the summertime when there is sunlight available 
in large amounts. There is also shown a correlation between the month of birth and 
MS incidence. Individuals born in the autumn show a low frequency of developing 
MS and individuals born in the spring show a higher frequency (Willer et al., 2005). 
This point to an interaction between genes and environmental factors related to 
climate during pregnancy or the first months of the child’s life. The environmental 
factors may be sun exposure and vitamin D3 level in the mother during pregnancy. If 
the sun exposure is high, it decreases the unborn child’s risk of developing MS. A 
lower frequency of MS is also observed in populations living 2000 meters above sea 
level. This may be due to the fact that these people are exposed of a more intense 
UVR (Schwalfenberg, 2012) 
 
Non-obese diabetic (NOD) mice are murine models of T1D, analogous to EAE mice 
as a model for MS. Both in EAE and NOD mice an increased severity of the diseases 
is seen in association with vitamin D3 restriction in the diet, leading to vitamin D3 
deficiency (Hewison, 2012). The same is shown in the corresponding human disease. 
In a study where 244 children recently diagnosed with T1D were examined, 51.2% 
had vitamin D3 deficiency (Raab et al., 2014). Among the 404 children that did not 
express islet antibodies only 28.3% had vitamin D3 deficiency (Raab et al., 2014). A 
study by Janner et al. supported the high frequency of vitamin D3 deficiency by 
showing that it occurred in 60.5% of 129 T1D patients (Janner et al., 2010). 
 
These two studies and the effects of calcitriol in immune function, indicate that a 
deficiency of calcitriol can contribute to autoimmunity. Calcitriol deficiency can be 
caused by a dysfunctional vitamin D metabolism, by lack of UVB light or by an 
inconvenient vitamin D intake in the diet. When an individual’s amount of vitamin D 
is measured, it is the amount of circulating 25(OH)D3 that is measured. This may in 
some cases not be a correct measurement to describe the individual’s level of 
calcitriol, because a dysfunctional vitamin D pathway, caused by a dysfunctional 
enzyme or a dysfunctional binding site, may lead to a lower or higher amount of 
calcitriol than expected from the measured amount of 25(OH)D3 (Holick F Michael, 
2004). The consequence is that an individual can suffer from calcitriol insufficiency 
even though the individual has sufficient amounts of 25(OH)D3. The conversion of 
the circulating 25(OH)D3 to calcitriol also affects immune function (Pierrot-
Deseilligny & Souberbielle, 2013). This is due to large amounts of 25(OH)D3 result in 
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expression of the 1α-hydroxylase in different cells, and not every cell express the 
enzyme in equal amounts. The calcitriol effect in cells is thus a result of the cell’s 
ability to engage in the vitamin D3 pathway combined with the amount of available 
circulating vitamin D3. In EAE models it has been shown that a low expression of 
VDRs contributes to the disease, by causing an increase in the amount of Th-1 and 
Th-17 cells. If VDRs are expressed in very low amounts, the calcitriol cannot be 
transported to the nucleus and bind to the promoter sequences. This suggests that the 
risk of MS can be increased even though the levels of vitamin D3 are sufficient 
(Pierrot-Deseilligny & Souberbielle, 2013). 
 
Vitamin D3 makes a shift in the CD4+ T-cell population by increasing Th-2 cells and 
T-regs proliferation and decreasing the proliferation of Th-1 and Th-17 cells. The 
suppression of Th-1 and Th-17 cells lead to a change in the cytokine expression of the 
T-cells, resulting in reduced amounts of the pro-inflammatory cytokines IL-17 and 
IL-1. This is shown to be the case in vitro, while in vivo the process may be a lot 
more complicated, and vitamin D3 may result in different CD4+ T-cells shifts 
(Pierrot-Deseilligny & Souberbielle, 2013). The Th-1 and Th-17 cells are important 
mediators of the autoimmune response causing T1D and MS. The suppression of 
these cells in the two diseases will lead to a reduced autoimmune response. In MS this 
suppression would result in a decreased migration through the BBB and blood-CSF-
barrier, because IL-17 directly facilitates this migration and IL-1 contributes to the 
migration as described earlier. The enhanced proliferation of T-regs is important for 
both MS and T1D because there in both cases is a failure in the regulation of the 
immune cells, leading to acceptance of auto-reactive T-cells. This could be prevented 
by the increase of T-regs induced by calcitriol.  
Calcitriol reduce the release of pro-inflammatory cytokines, the expression of 
adhesion molecules, and the expression of MHC class I and II molecules, thereby 
decreasing the APC’s ability to activate CD4+ and CD8+ T-cells. Calcitriol reduces 
the synthesis of the chemokine CXCL10, and other pro-inflammatory chemokines 
(Wolden-Kirk et al., 2011). Hyperexpression of MHC class II molecules is observed 
in both MS and T1D, and the CD4+ T-cells are key components of the autoimmune 
response in both the diseases. If the hyperexpression is lowered by calcitriol and the 
CD4+ T-cells are not activated by the auto-antigen presenting MHC class II 
molecules, calcitriol would have an anti-autoimmune effect in both MS and T1D.  
VDRs are also found in the CD8+ T-cells and it has been shown that vitamin D3 
regulates cytokine synthesis in CD8+ T-cells. The proliferation of CD8+ T-cells has 
not been shown to be affected by vitamin D3. This means that vitamin D3 cannot 
prevent the CD8+ T-cells from causing damage once they are activated, but vitamin 
D3 can affect them to synthesize anti-inflammatory cytokines and stop the activation 
of additional CD8+ T-cells. Vitamin D3 influences the proliferation of B-cells and the 
production of Igs. B-cells are found to contribute to the pathogenesis of both MS and 
T1D and calcitriol could prevent the harmful effects of these B-cells (Hewison, 2012). 
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One of the key effects of vitamin D3 is that it suppresses the activation of naive T-
cells. This effect is due to the suppressed differentiation of monocytes to DCs. 
Calcitriol induces the DCs to stay in their immature form. In mature DCs there are 
found lower levels of VDRs than in monocytes and immature DCs. Mature DCs are 
thus less influenced by 25(OH)D3 than immature DCs. In contrast to this the maturing 
process of the DCs enhances the production and release of calcitriol. The mature DCs 
are therefore able to convert more calcitriol than immature DCs. When the mature 
DCs produce and release more calcitriol, the immature DCs will be more influenced. 
The result is that the mature DCs, which are insensitive to 25(OH)D3, will present 
antigens and initiate an immune response, but when vitamin D3 levels are high they 
will produce calcitriol in amounts so high that prevents the maturation of immature 
DCs and present antigens. Vitamin D3 in sufficient amounts will therefore allow DCs 
to initiate antigen presentation and simultaneously prevent further maturing of DCs 
presenting antigens, and thus prevent an overstimulation of T-cells (Hewison, 2012). 
When mature DCs are cultivated with calcitriol they undergo apoptosis, the same 
happens with auto-reactive T-cells, which also shows decreased proliferation when 
cultivated with calcitriol (Wolden-Kirk et al., 2011). If an overstimulation of auto-
reactive T-cells are prevented by calcitriol, and calcitriol eliminates the mature DC’s 
presentation of auto-antigens, calcitriol could thereby prevent the occurrence of parts 
of the immune response in both T1D and in MS. 
    
β-cells show an expression of VDRs and is thus a target for calcitriol. Calcitriol 
therefore might have beneficial effects in T1D, other than the effects in immune 
function. Calcitriol might affect the β-cells response to metabolic stress and the 
response of cytokine mediated cell death. The reason calcitriol has an effect on this 
response might be due to its binding to genes involved in signalling, antigen 
presentation, and chemotaxis (Wolden-Kirk et al., 2011)      
 
It is a fact, which still lacks a precise explanation, that women develop MS more 
frequently than men. Another difference between the sexes is observed in vitamin D 
metabolism in EAE models. In EAE models it has been shown that females benefit 
more from vitamin D3 than males and that females need a smaller amount of vitamin 
D3 to prevent disease (Spach & Hayes, 2005). This is due to an enhancing effect of 
estrogens. The estrogen is hypothesized to inhibit the expression of the gene 
CYP24A1 in the spinal cord. The gene product, the enzyme 24-hydroxylase, makes 
an inactive metabolite of 25(OH)D3. It is hypothesized by Spach & Hayes that 
estrogens cause inactivating of CYP24A1, this is due to an estrogen sensitive element 
in the IFN-γ promoter (Spach & Hayes, 2005). Binding of estrogen to the promoter 
induces the expression of IFN-γ. More IFN-γ is thus produced and it terminates 
CYP24A1 expression in the activated macrophages. When CYP24A1 gene expression 
is inhibited indirectly by estrogen the circulating vitamin D is degraded much slower 
and therefore calcitriol can accumulate in the target cells, here CNS, where it prevents 
further inflammation and preceding MS (Spach & Hayes, 2005).  
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If humans also have this sex difference in vitamin D metabolism, it could suggest that 
hormone treatment may be beneficial. Males do not completely inactivate CYP24A1 
in the spinal cord, and do therefore not accumulate calcitriol that prevents further 
development of MS. They do therefore not have the same anti-inflammatory benefits 
from vitamin D3 as females because of the lacking synergetic effect between vitamin 
D3 and estrogens. Males degrade vitamin D3 more efficient than females and a larger 
amount are needed to cause the same beneficial effects (Spach & Hayes, 2005). A 
study made by Correale et al. has supported differences between the sexes, by 
showing that healthy females as well as MS female patients benefit more from 
calcitriol then males (Correale, Ysrraelit, & Gaitán, 2010). 
 
Linking between vitamin D insufficiency and some autoimmune diseases have been 
established. The HLA-DRB1*1501 allele is one of the alleles that are associated to 
the development of MS. Within the promoter region of HLA-DRB1 some VDREs are 
found that influence the gene expression. In HLA-DRB1*1501 the VDRE in the 
promoter region is regulated by calcitriol, which means that this gene is sensitive to 
vitamin D (Pierrot-Deseilligny & Souberbielle, 2013). 
Other HLA-DRB1 alleles, not associated with MS, were not sensitive to calcitriol and 
do therefore not respond to calcitriol. This mean that in the HLA-DRB1*1501, gene 
expression is either supressed or promoted depending on the level of calcitriol, and in 
other HLA-DRB1 the genes are expressed independently of calcitriol.  
The frequency of HLA-DRB1*1501 is higher in people with lighter skin colour, and 
it is higher in females compared to males (Pierrot-Deseilligny & Souberbielle, 2013).  
 
Calcitriol’s effect is also seen in other parts of the immune system. Calcitriol binds to 
VDRs on the T-reg cell, which reduce the Th-1 activity and restores the balance 
between Th-1 and Th-2, see Figure 20 in The influence of vitamin D in Multiple 
Sclerosis. Vitamin D insufficiency could have a major effect in MS, since it would 
shift the balance between Th-1 and Th-2 cells, and in this way promote the 
development of MS by shifting the balance to be Th-2 dominant (Pierrot-Deseilligny 
& Souberbielle, 2013).  
 
It is not only the HLA-DRB1 gene that can be associated with the level of calcitriol.  
In a study by Lopez et al. there is found evidence that polymorphisms in CYP27B1 
are associated with T1D (Lopez et al., 2004). A C/A polymorphism are found 
promoter region of CYP27B1, the promoter polymorphism C, occur more frequently 
in patients suffering from T1D (Lopez et al., 2004). If CYP27B1 is mutated, leading 
to a decreased action of 1α-hydroxylase, it could cause a low calcitriol level, even 
though the level of vitamin D3 in its active circulating form is relatively high (Pierrot-
Deseilligny & Souberbielle, 2013).  This could play a role in the development of T1D 
as well as MS, since calcitriol is important in the maintenance of the immune system, 
and most likely reduce the risk of developing any autoimmune diseases.  
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Vitamin D insufficiency alone is not enough to develop MS or T1D, other 
environmental factors and the genetic of the individual play a role as well (Pierrot-
Deseilligny & Souberbielle, 2013).  
Both in MS and T1D, a connection to blood level of the vitamin D3, in the 
development and progression of both diseases is seen.  
Another gene, important for the regulation of the calcitriol level, is CYP25A1. This 
gene codes for the enzyme 24-hydroxylase, which has the opposite effect on the 
calcitriol level compared to the 1α -hydroxylase. CYP25A1 induces an inactivating 
pathway, reducing the amount of free calcitriol in the blood, and is regulated by the 
level of calcitriol and fibroblast growth factor 23 (FGF23), which is a phosphaturic 
hormone (Pierrot-Deseilligny & Souberbielle, 2013). This regulation provided by 24-
hydroxylase can be a factor in the development of MS and T1D. If the gene is altered 
in a way that makes it overexpressed or makes the enzyme more reactive, a high 
amount of vitamin D3 could be inactivated resulting in calcitriol deficiency. If this is 
the case in T1D and MS patients, an increased amount of vitamin D3 would not have 
an effect in calcitriol levels and vitamin D3 treatment could not prevent or resolve the 
diseases.     
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The immune response in Multiple Sclerosis and Type 1 Diabetes  
Th-1 and Th-2 cells exert a negative regulation on each other, and their effector 
cytokines IFN-γ and IL-4 respectively act by downregulating the expansion of Th-17 
cells. Uncontrolled Th-1 response against auto-antigens can lead to the development 
of autoimmunity and research shows that Th-1 cells act as the major effector T-cell 
responsible for inducing EAE progression and potentially MS (Bedoya, Lam, Lau, & 
Iii, 2013). Th-1 effector mechanisms seemed to explain many histopathological and 
clinical features not only in EAE but also in other autoimmune diseases, including 
T1D. Th-1 cells therefore became the archetypical inducer of organ specific 
autoimmunity. Conversely, Th-2 cells are found incapable of inducing autoimmune 
tissue inflammation (Freiesleben et al., 2010).  
The damaging effect of Th-1 cells and the protecting effect of the Th-2 cells are 
supported by the fact that Th-1 cells are more abundant than Th-2 cells in MS and 
T1D patients, these have a higher Th-1 to Th-2 ratio than healthy individuals. This 
suggests that this uneven ratio contributes to the cause of autoimmune diseases. The 
effects of Th-1 cells are to secrete pro-inflammatory cytokines, and in this way create 
or enhance an immune response. The opposite effect is induced by Th-2 cells. 
Therefore it could be beneficial to shift this ratio in order to decrease or prevent an 
autoimmune response. A correct regulated adaptive immune system have therefore 
been said to dependent on a balanced ratio of Th-1 and Th-2 cells, but the 
mechanisms of the immune system are now considered more complex than this. The 
role of Th-17 cells and T-regs are now considered to influence the immune regulation 
and has an effect of equal importance. Th-17 cells are present at the sites of tissue 
inflammation, are mediators of autoimmune tissue injuries, and are developmentally 
distinct from Th-1 and Th-2 cells (Freiesleben et al., 2010).   
During MS and T1D, Th-17 cells may be critical mediators of immune destruction of 
myelin and axons because of their production and induction of inflammatory 
cytokines and other proteins (Bedoya et al., 2013; Zhang, Shih, & Zhang, 2013).  
The Th-17 cells secrete IL-17, this cytokine induce the cytokine production in other 
effector T-cells. IL-17 also induces endothelial cells and macrophages to produce 
chemokines and induces the cytokine production in macrophages (Freiesleben et al., 
2010). The endothelial production of chemokines contributes to immune cell 
migration to the endothelial. Chemokine production in endothelial cells are observed 
in the BBB in MS patients where it contributes to immune cells migration to the BBB. 
The fact that Th-17 cells are active in MS patients suggests that IL-17 might act on 
the endothelial of the BBB. Furthermore it is shown that IL-17 contributes to the 
breakdown of the BBB, by directly binding to IL-17 receptors on the BBB.  
Th-17 cells are also found in the peripheral blood of T1D patients, and it has been 
shown that IL-17 is toxic for islets in vitro. IL-17 has a synergetic toxic effect with 
the pro-inflammatory cytokines IL-1β, IFN-γ and TNF-α (Bending et al., 2012).  
The fact that vitamin D3 inhibits the production of Th-17 cells and has a positive 
influence on the patients, suggest that the Th-17 cells has a damaging role in the two 
diseases.  
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Th-17 cells are most likely involved in the severity of the disease and acts in the 
progression of the disease, but they are not the reason T1D occurs. Th-17 cells cannot 
induce T1D unless it converts to a cell similar to Th-1. Only these cells can induce 
T1D (Bending et al., 2012). T-regs secrete the cytokine IL-10. This cytokine plays a 
role in immune regulation of T1D and also plays an important role in the progression 
of the disease. This is due to the anti-inflammatory and tolegenic effect described 
earlier. IL-10 inhibits upregulation of MHC class I and II in many cell types, inhibits 
Th-1 differentiation, and prevent the activation of macrophages (Freiesleben et al., 
2010). This effect could be beneficial in regards to MS and T1D. A reduction in T-
regs would lead to a loss of tolerance and an enhanced immune response, this 
reduction is observed in context with vitamin D3 insufficiency and may be one of the 
reasons that vitamin D3 insufficiency contributes to autoimmunity.  
NOD studies by Emamaullee et al. showed that the mice that received a neutralizing 
anti-IL-17 antibody, which was expressed in the pancreas, resulted in inhibition of IL-
17 and were able to prevent the development of T1D (Emamaullee et al., 2009). 
These observations could suggest that the absence of Th-17 cells is important in 
delaying the removal of insulin-producing pancreatic β-cell. 
 
T1D and MS are a CD4+ and CD8+ T-cell mediated autoimmune disease. Both 
diseases are characterized by inflammatory actions provided by Th-1 and Th-17 cells. 
In MS, Th-1 cells secrete TNF-γ and Th-17 cells secrete IL-17 and IL-22 cells which 
contribute in migration to the BBB. The cytokines facilitate the disruption of the BBB 
and migration of CD4+ and CD8+ T-cells to the CNS. In this way they contribute to 
mediate the immune response in MS.  Hereby an inflammatory reaction is initiated, 
that stimulates other immune cells such as cytokines. The process leads to further 
leakage of the BBB and further release of cytokines. In T1D, Th-17 cells also secrete 
IL-17, which recruits neutrophils and macrophages. This recruitment is also 
facilitated by other cytokines.  
The macrophages contribute to the destruction of β-cells by secreting pro-
inflammatory cytokines, such as TNF-α and IL-1β. This suggests that some of the 
same autoimmune response mechanisms cause MS and T1D. Both diseases are 
caused by T-cells secreting pro-inflammatory cytokines and B-cells and plasma cells 
secreting antibodies.  However the immune responses are not identical. The main 
difference is that the adaptive and innate immune system targets different auto-
antigens. Another difference is that the MS immune response is dependent of the 
BBB or blood-CSF barrier breakdown. The BBB breakdown is among others caused 
by Th-17 cells secreting IL-17 this could suggest that the th-17 cells has a larger 
influence in MS than T1D, and that the MS immune response are more dependent of 
Th-17 cells.    
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The fact that some mechanisms are the same leads to the suggestion that if the target 
is somehow changed an autoimmune response will be initiated against this new auto-
antigen leading to several autoimmune responses. This auto-antigen change might be 
caused by defects in the selection of T-cells, which might lead to the development of 
additional auto-reactive. If the selection first fails in a way that allows β-cell specific 
T-cells to develop one could imaging that the selection also could fail in a way that 
allows myelin-specific T-cells to develop. In this way several autoimmune diseases 
could exist simultaneously.  
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Conclusion 
MS and T1D are autoimmune diseases where the immune system produces antibodies 
against the body’s own tissue.  
The immune response in MS is caused by B- and T-cells that attack the myelin 
sheaths’ auto-antigens in the CNS. This is due to the specific T-cells passing the BBB 
and blood-CSF barrier. The T-cells in the CNS activate B-cells and plasma cells by 
the release of chemokines and cytokines. The cytokines released from B-cells result in 
the migration of DCs and active macrophages and activate additional B-cells and 
plasma cells. This lead to the conclusion that the plaques and demyelination in MS is 
formed due to invading T-cells which reacts on myelin sheaths in CNS. 
In T1D the immune response targets the β-cells in the pancreas, where insulin 
deficiency will happen due to the destruction of the β-cells. This destruction is due to 
CD4+ and CD8+ T-cells which mediate the adaptive autoimmune response. The 
macrophages are important in this immune response, because they secrete cytokines 
such as IL-1β and TNF-α, which result in an inflammatory state and attract additional 
immune cells to eliminate the β-cells.  
 
We can conclude that genetic factors as well as vitamin D have an effect on the 
progression of MS and T1D. Of the HLA genes 40% are associated with MS 
susceptibility, where the specific HLA-DRB1*1501 gene have the strongest 
association to the development. Therefore all genetic combinations where this specific 
gene is involved, greatly increases the risk of developing MS.  
HLA alleles account for 50% of the genetic risk in developing T1D. The HLA class II 
genes, primarily the HLA-DRB1, the HLA-DQA1 and the HLA-DQB1, have a major 
role in the genetic susceptibility for T1D. Both diseases are associated with the HLA-
DRB1 gene encoding the MHC class II molecule, which could indicate a shared 
inheritance and could explain the reason why an individual with the organ specific 
disease MS has a higher risk of developing the organ specific and systemic disease 
T1D, or vice versa.  
The SNPs, rs12708716, rs725613, and rs6498169, in CLEC16A are associated with 
the development of T1D and MS. Mutations in these SNPs affect the immune 
regulatory cells; CIITA, SOCS1, and DEXI in CLEC16A. This result in a 
dysfunctional cytokine signalling, downregulation of MHC class II molecules, and 
inhibition or prevention of activity of the immune system during autoimmune 
responses.     
 
Vitamin D3 has a preventive effect on the development of both diseases.  
Calcitriol is the active metabolite of vitamin D3, which has a potential to influence 
gene expressed by the immune cells. Calcitriol deficiency is caused by a 
dysfunctional vitamin D metabolism, lack of UVR light, or by an inconvenient 
vitamin D intake in the diet.   
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Women benefit more from vitamin D and therefore need a smaller amount to prevent 
MS and T1D. This is due to the enhancing effect of estrogens, which in EAE inhibits 
the expression of the gene CYP24A1 in the spinal cord.  Therefore the fact that MS is 
more often expressed in women compared to men cannot be finally explained without 
further research. The anti-inflammatory effect provided by vitamin D is concluded to 
be a result of the shift in the CD4+ T-cells, by increasing Th-2 cells and T-regs 
proliferation and decreasing the proliferation of Th-1 and Th-17 cells. The 
suppression of Th-1 and Th-17 cells reduces the number of pro-inflammatory 
cytokines, which results in a reduced autoimmune response. Th-17 cells have a pro-
inflammatory effect, which was previously attributed to Th-1 cells. Th-1 cells still 
have a major pro-inflammatory effect but it is now concluded that Th-17 cells are also 
key mediators of this response.  
 
Due to vitamin D’s immune regulatory function and gene interaction, vitamin D 
insufficiency contributes to the development of MS and T1D. In addition to this, it is 
most likely that people with certain HLA alleles have an enhanced susceptibility for 
MS and T1D. Because genetic factors and vitamin D have an influence in immune 
mechanisms that are the same in the pathogenesis of both diseases, it is most likely 
not a coincidence that individuals affected with one autoimmune disease, develops 
another such as MS and T1D. 
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Further Prospects 
Besides having discovered that vitamin D has an influence on the development of MS 
and T1D (Pierrot-Deseilligny & Souberbielle, 2013; Schwalfenberg, 2012), another  
study show that vitamin D has an influence on other immune diseases as well 
(Stankov et al., 2013). These diseases are shown in Figure 28. It might be interesting 
to investigate if vitamin D insufficiency has a bigger influence on autoimmune 
diseases than the genetic factors, and if vitamin D supplements can be used in 
autoimmune disease treatment or prevention.  It might also be interesting to study the 
interacting of calcitriol and genes associated with the diseases and immune regulatory 
genes.     
 
 
Figure 28 shows other autoimmune diseases, observed in an animal study, which are influenced by the 
active metabolite of vitamin D, the steroid hormone calcitriol 1,25(OH)2D. Modified (Schwalfenberg, 2012). 
In this report it has been concluded that environmental factors also influences the 
development of MS and T1D. Further studies involving these environmental factors, 
such as smoking, could be interesting to investigate as well.  A new in vitro study 
made by Pooja & Neal shows that tobacco smoke release a significant amount of 
reactive oxygen species (ROS), which could in fact have an influence on several 
neurological diseases including MS (Pooja & Neel, 2014). ROS is produced by the 
phagocyte NADPH oxidase (NOX2) complex and has been considered a harmful 
mediator of inflammation, because they are highly reactive (Chen, Gusdon, Thayer, & 
Mathews, 2013). The study by Pooja & Neal suggests that cigarette extract from 
cigarettes induces an inflammatory response in the endothelial cells in BBB, but also 
a progressed ROS damage in other cells (Pooja & Neel, 2014). Because the BBB is 
the main structure protecting the part of CNS located in the brain, this would be 
relevant to further research, additionally because ROS are important mediators of β-
cells elimination during the development of T1D (Chen et al., 2013).   
Furthermore, there are studies showing that the Epstein bar virus (EBV) has an 
influence on the development of MS. This is interesting because 90% of the world’s 
population are infected with this type of virus during the first years of childhood 
(Angelini et al., 2013).  
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Table 1: Agents that trigger autoimmune disease.
Infections Epstein-Barr’s virus, cytomegalovirus, parvovirus, enteropathogenic bacteria
Vaccine immunogens
Multiple sclerosis, Guillain-Barre’s syndrome, autism, rheumatoid arthritis,
reactive arthritis, systemic lupus erythematosus, diabetes, vasculitis,
dermatomyositis, polyarteritis nodosa
A juvants used to enhance immune response Lupus erythematosus, brain directed autoantibodies, arthritis, nephritis
Birth control, pregnancy Autoimmune thyroid disease
Smoking
Rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis,
Graves’ hyperthyroidism, Crohn’s disease
Stress Type 1 diabetes, Grav ’s disease
Adapted from [3, 4].
Table 2: Autoimmune diseases that are inhibited by 1,25(OH)2D
in animal studies [6].
Autoimmune encephalomyelitis
Collagen-induced arthritis
Inflammatory bowel disease
Type 1 diabetes
Systemic erythematosus
Thyroiditis
Lyme arthritis
Rheumatoid arthritis
Multiple sclerosis
Figu e 1: Autoimmune disease causation triangle. Adapted fro
[9]. Used with permission.
available in some foods and supplements or produced in the
skin from 7-dehydrocholesterol after exposure to ultraviolet
B light. The resulting previtamin D is then hydroxylated
in the liver to hydroxyvitamin D (25(OH)D) and further
hydroxylated in the kidney to 1,25-dihydroxyvitamin D
(1,25(OH)2D) which is the active hormone involved in
calcium absorption in the gut. Circulating 25(OH)D (which
is considered the measure of vitamin D adequacy) may
also be used as substrate in many cells to locally produce
(1,25(OH)2D), the active hormone, via the CYP27B1 (1α-
hydroxylase) enzyme and is inactivated by the CYP24A (24-
hydroxylase) enzyme [14]. The classical role of vitamin
D is to regulate calcium homeostasis [15]. Short latency
diseases, such as rickets and osteomalacia, can be cured with
25(OH)D levels > 25 nmol/L. In a long-latency disease, such
as osteoporosis, levels of 25(OH)D > 50 nml/L have been
shown to reduce fractures.
In the last twenty years, the importance of vitamin D in
the role of a hormone has been shown to influence numerous
other diseases including cancer by increasing apoptosis in
cancer cells and protecting DNA in normal cells [16]. Its
effect on the immune system and infections is only beginning
to be understood, and much higher doses of vitamin D may
be needed to be effective in combating viruses, bacteria, and
fungi [17]. Vitamin D is now recognized to be crucial in beta-
defensin production in Crohn’s disease [18].
The role in regulating the immune system in regards to
self-tolerance and autoimmunity begins with an understand-
ing of the impact of vitamin D on our genes. Research is
showing that there are 2776 “binding sites” on the human
genome to which vitamin D attaches, with at least 229
genes associated with Crohn’s disease and type 1 diabetes
[19]. Many of the sites are concentrated around genes
linked to autoimmune conditions as described in this paper.
Beyond this, vitamin D suppresses autoimmune disease
pathology by regulating differentiation and activity of CD4+
T cells resulting in a more balanced T1/T2 response favoring
less development of self-reactive T cells and autoimmunity
[2].
3. Multiple Sclerosis
In regards to the host, it is known that only 30% of monozy-
gotic twin pairs eventually get multiple sclerosis (MS) leading
us to believe that exposure to one ormore environmental risk
factors is necessary for the development ofMS [20]. Recently,
two large genomic studies have confirmed the unambiguous
associations with the DRB1 and DQB alleles of the human
leukocyte antigen class II region and susceptibility to MS
[21].
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The EBV infects the B-cell and epithelial cells, and Angelini et al. furthermore 
suggested that CD8+ T-cells activates EBV, therefore EBV could be a reason why 
MS is developed (Angelini et al., 2013). This could be of interest in further research, 
due to the knowledge of the CD8+ T-cells interaction against myelin sheaths in MS. 
EBV infection is found in almost every MS patients and people that are infected later 
in life, during their teens, have a two to three times enhanced risk of developing MS 
compared to people infected early in life (Comabella & Khoury, 2012). There is also 
a study suggesting that EBV has an influence on the development of T1D, and a 
tendency of several patients first diagnosed with EBV and afterwards developed T1D 
has been seen (Fujiya et al., 2010).   
As mentioned, lymphoid like structures are found in the meninges of MS patients, 
these are found together with EBV infectious material in the patients. It is suggested 
that the EBV infected B-cells mediates the further maturing of B-cells and drives the 
generation of these lymphoid structures in the meninges, and thus promotes the local 
control of B-cells and plasma cells. This role of infection in autoimmunity is not 
restricted to EBV, other infection agents are suggested to trigger the activation of 
auto-reactive T-cells too (Magliozzi et al., 2007). The effects of the EBV and other 
viruses could be interesting to study too figure out how they can potentially lead or 
contribute to the development of autoimmunity.   
 
GWAS have showed several similarities between autoimmune disease genetics, seen 
in Figure 29, on the next page, it would be interesting to examine other genes that the 
autoimmune diseases have an association to (Stankov et al., 2013). One of the genes 
of interest is the CD58 gene. CD58 has been proven to have allelic variants in the 
gene region, encoding Leukocyte Functional Antigen (LFA-3). LFA-3, the co-
stimulatory molecule, is a cell adhesion molecule expressed on APCs, and is 
suggested to have a association with the risk of developing MS because CD58 is 
involved in T-cell activation (Davis & Metwe, 1996; Goris et al., 2012; Jager et al., 
2009; Janeway et al., 2001)  
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Figure 29 shows five different autoimmune diseases, including T1D and MS, and the genes they have in 
common (Stankov et al., 2013). 
The development, maintenance, metabolism and regeneration of the β-cells in T1D 
can also be influenced by epigenetic mechanisms, which could be interesting for 
further studies. The activation of T-cells, induction of T-regs and other immune 
response mechanisms rely on an appropriate epigenetic regulation. In addition to this, 
the epigenome of certain tissues, such as the liver and the tissue in the pancreas, is 
influenced by the metabolism of glucose and insulin. Such changes in the epigenome, 
due to this metabolism, could be associated with T1D characteristics (Stankov et al., 
2013). In T1D there is a hypomethylation due to a decreased DNA methyltransferase 
activity, these methylating defects results in a potential deregulated gene expression 
and chromosome instability that increases the susceptibility of T1D. It has been 
shown that T1D patients have gene sequences with both hyper- and hypomethylation. 
This is shown in the promoter region of the INS gene, which is associated with T1D 
susceptibility (Fradin et al., 2012).  A study has also shown epigenetic changes in 
T1D patients in HLA-DQB1 and in GAD2, which encode GAD65 which as 
mentioned before is an antigen in T1D (Rakyan et al. 2011).   
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Abnormal levels of miRNAs has also been shown in T1D patients (Hezova et al., 
2010). These miRNAs can influence the development of T1D by regulating gene 
expression by targeting transcripts in cell cytoplasm. Post-transcriptional 
modifications of the N-terminal on histone tails, is suggested to affect the 
development of T1D, because they can be altered by diabetic stimuli, for example 
hyperglycemia (Miao et al., 2008). These post-transcriptional modifications may be: 
acetylation, phosphorylation, methylation, and ubiquitination, These modifications 
have been detected in the promoters of several genes associated with T1D 
susceptibility (Stankov et al., 2013). 
 
There are also studies that suggest that the regulation and selection of T-cells are 
dysfunctional and this contributes to induce autoimmunity.  Vitamin D is suggested to 
influence the lymph nodes and in this way the insufficiency of vitamin D could 
contribute to the failure of lymphocyte selection (Pierrot-Deseilligny & Souberbielle, 
2013). It could be interesting to study the selection in autoimmunity in order to find 
out if it varies from healthy people, which could allow the development of auto-
reactive T-cells.  
T-regs found in the peripheral blood of MS patients have also suggested to be 
dysfunctional in a way that makes them unable to suppress the activation of myelin 
specific T-cells (Comabella & Khoury, 2012). It could be interesting to study the T-
regs within the CNS and see if these also show this dysfunction. A kind of T-regs 
where actually found absent in the brain this could suggest that the T-regs fails to 
migrate to the CNS or are eliminated once they enter the CNS.  This absence of T-
regs is not found in EAE where the T-regs accumulate (Comabella & Khoury, 2012). 
This absence points to a difference between MS and EAE.    
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Appendix 1 
Word list 
Antigen-presenting cell (APC) 
Cells that presents antigens via MHC molecules. 
Professional APCs are macrophages, DCs and B-cells, associated with MHC 
class II.  
Apoptosis 
 Programmed cell death. Induced by intracellular signals. 
Blood Brain Barrier (BBB) 
A barrier found between the blood circulation and the brain fluid. Function as 
selective barrier.  
Blood-cerebrospinal fluid (CSF) barrier 
A barrier that surrounds the spinal cord. Function as selective barrier. 
CD4+ T-cells 
Also known as helper T-cells. CD4+ T-cells are bound to and activated by 
MHC class II molecules. Involved in the activity of other immune cells. 
CD8+ T-cells 
Also known as cytotoxic T-cells. Recognizes antigens presented by MHC 
class I complex. Due to their toxicity they induces lysis of the presenting cell.   
Central nervous system (CNS) 
 The part of the nervous system that consist of the brain and spinal cord. 
Dendritic Cell (DC)  
An antigen presenting cell. Descends from myeloid and lymphoid stemcells. 
Major function is antigen presentation with MHC class II.  
Experimental autoimmune encephalomyelitis (EAE) 
A murine model of brain inflammation, analogous to MS. It is used to gather 
information about demyelinating diseases in the CNS.    
Human Leukocyte Antigen (HLA) 
A group of genes, made up by multiple alleles, that encode the MHC 
molecules.  
Immunoglobulin (Ig) 
An antibody protein produced by B-cells. The membrane bound proteins are 
found on the naive B-cell, and free Igs are secreted by plasma cells. 
Interferon (IFN) 
A cytokine with a regulating function in the immune system. Are secreted as a 
response to an invading pathogen 
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Interleukin (IL) 
A group of cytokines which induces inflammation in target areas. Secreted by 
immune cells, which they also affects the development of. 
Invariant natural killer T-cells (iNKT) 
A lymphocyte, with characteristics of both the T-cells and the NK cells. 
Secretes cytokines, involved in the immune response, and are able to kill 
infected or invading cells.  
Major histocompatibility complex (MHC) 
A surface molecule, required in the antigen presenting process. It is found on 
the surface of APCs and inside the cell. There are two different classes, class I 
and II.  
Multiple Sclerosis (MS) 
An autoimmune inflammatory disease where nerve cells in the brain and 
spinal cord are damaged.  
Murine model  
Experiment conducted in mice. 
Natural killer (NK) cells 
Cytotoxic lymphocytes without B- or T-cell receptors. NK cells are critical to 
the innate immune system because they provide response to viral infected 
cells.    
Necrosis 
 Cell death induced by an extracellular signal.  
Non-obese diabetic (NOD) 
A murine model of T1D, used as an analogue for the disease. Used to study 
insulin deficiency. 
Pattern recognition receptors (PRR) 
Receptors functioning in the innate immune system. Recognizes specific 
molecular patterns presented by an invading pathogen.  
Regulatory T-cells (T-regs) 
A sub population of T-cells, which play a role in the T-cell tolerance 
development and the immune system.  
Th-1 cells 
A CD4+ T-cells that produce pro-inflammatory cytokines and are involved in 
activating macrophages. Secretes cytokines, for example IL-2.  
Th-2 cells 
A CD4+ T-cells that produce anti-inflammatory cytokines and are involved in 
stimulating B-cells to produce antibodies. Secretes IL-2, IL-4, IL-6 and other 
cytokines. 
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Th-17 cells 
A CD4+ T-cell, which produces IL-17, and aids in inflammation.  
Toll-like receptors (TLR) 
Receptor found on the surface of monocytes, and cells differentiated from 
monocytes. Recognizes some pathogens due to the surface molecules.  
Type 1 diabetes (T1D) 
An autoimmune disease that occurs when the immune system attacks and 
destroys the insulin-producing β-cells in the pancreas. 
 
Modified (Goldsby et al., 2003; Janeway et al., 2001; VanPutte et al., 2013). 
